PRODUCT MONOGRAPH

Pr ZOMIG® (zolmitriptan) tablets
   2.5 mg

Pr ZOMIG RAPIMELT® (zolmitriptan) orally disintegrating tablets
   2.5 mg

Pr ZOMIG® NASAL SPRAY (zolmitriptan) nasal spray
   2.5 and 5 mg

5-HT1 Receptor Agonist

MIGRAINE THERAPY

AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, Ontario
L4Y 1M4
www.astrazeneca.ca

Date of Revision: December 11, 2019

Submission Control No.: 231420

ZOMIG® and ZOMIG RAPIMELT® are registered trademarks of IPR Pharmaceuticals, Inc., used under license by AstraZeneca Canada Inc.
# TABLE OF CONTENTS

## PART I: HEALTH PROFESSIONAL INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUMMARY PRODUCT INFORMATION</td>
<td>3</td>
</tr>
<tr>
<td>INDICATIONS AND CLINICAL USE</td>
<td>3</td>
</tr>
<tr>
<td>CONTRAINDICATIONS</td>
<td>4</td>
</tr>
<tr>
<td>WARNINGS AND PRECAUTIONS</td>
<td>4</td>
</tr>
<tr>
<td>ADVERSE REACTIONS</td>
<td>11</td>
</tr>
<tr>
<td>DRUG INTERACTIONS</td>
<td>19</td>
</tr>
<tr>
<td>DOSAGE AND ADMINISTRATION</td>
<td>20</td>
</tr>
<tr>
<td>OVERDOSAGE</td>
<td>22</td>
</tr>
<tr>
<td>ACTION AND CLINICAL PHARMACOLOGY</td>
<td>22</td>
</tr>
<tr>
<td>STORAGE AND STABILITY</td>
<td>25</td>
</tr>
<tr>
<td>DOSAGE FORMS, COMPOSITION AND PACKAGING</td>
<td>26</td>
</tr>
</tbody>
</table>

## PART II: SCIENTIFIC INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHARMACEUTICAL INFORMATION</td>
<td>27</td>
</tr>
<tr>
<td>CLINICAL TRIALS</td>
<td>28</td>
</tr>
<tr>
<td>DETAILED PHARMACOLOGY</td>
<td>32</td>
</tr>
<tr>
<td>TOXICOLOGY</td>
<td>34</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>38</td>
</tr>
</tbody>
</table>

## PART III: CONSUMER INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONSUMER INFORMATION</td>
<td>40</td>
</tr>
<tr>
<td>CONSUMER INFORMATION</td>
<td>44</td>
</tr>
</tbody>
</table>
**ZOMIG®** (zolmitriptan) tablets
2.5 mg

**ZOMIG RAPIMELT®** (zolmitriptan) orally disintegrating tablets
2.5 mg

**ZOMIG® NASAL SPRAY** (zolmitriptan) nasal spray
2.5 and 5 mg

**PART 1: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<table>
<thead>
<tr>
<th>Product</th>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients*</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZOMIG®</td>
<td>oral</td>
<td>conventional tablet / 2.5 mg</td>
<td>anhydrous lactose</td>
</tr>
<tr>
<td>ZOMIG RAPIMELT®</td>
<td>oral</td>
<td>orally dispersible tablet / 2.5 mg</td>
<td>none</td>
</tr>
<tr>
<td>ZOMIG® NASAL SPRAY</td>
<td>intranasal</td>
<td>nasal spray / 2.5 mg, 5 mg</td>
<td>none</td>
</tr>
</tbody>
</table>

* For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING.

**INDICATIONS AND CLINICAL USE**

**Adults**

ZOMIG (zolmitriptan) is indicated for the acute treatment of migraine attacks with or without aura.

ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, basilar, or ophthalmoplegic migraine (see CONTRAINDICATIONS). Safety and efficacy have not been established for cluster headache, which is present in an older, predominantly male population.

**Pediatrics (< 12 years of age)**

The safety and efficacy of ZOMIG have not been studied in children under 12 years of age. Use of the drug in this age group is, therefore, not recommended (see WARNINGS and PRECAUTIONS, Special Populations).

**Adolescents (12-17 years of age)**

The safety and efficacy of ZOMIG have not been established in patients 12-17 years of age. The use of ZOMIG in adolescents is, therefore, not recommended (see WARNINGS AND PRECAUTIONS, Special Populations).
Geriatrics (> 65 years of age)
The safety and efficacy of ZOMIG in patients over 65 years has not been established and its use in this age group is not recommended (see WARNINGS AND PRECAUTIONS, Special Populations).

CONTRAINDICATIONS
ZOMIG (zolmitriptan) is contraindicated under the following conditions:

- in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases (e.g., atherosclerotic disease, congenital heart disease) should not receive ZOMIG. Ischemic cardiac syndromes include, but are not restricted to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal’s variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks (TIAs). Peripheral vascular disease includes, but is not limited to, ischemic bowel disease, or Raynaud’s syndrome (see WARNINGS AND PRECAUTIONS, Cardiovascular);

- in patients with uncontrolled or severe hypertension as ZOMIG can give rise to increases in blood pressure (see WARNINGS AND PRECAUTIONS, Hematologic);

- within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide (see DRUG INTERACTIONS);

- in patients with hemiplegic, basilar or ophthalmoplegic migraine;

- concurrent administration of MAO inhibitors or use of zolmitriptan within 2 weeks of discontinuation of MAO inhibitor therapy (see DRUG INTERACTIONS);

- in patients with hypersensitivity to zolmitriptan or any component of the formulation (for a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING).

WARNINGS AND PRECAUTIONS
General
ZOMIG (zolmitriptan) should only be used where a clear diagnosis of migraine has been established.

Lactose: Lactose is a non-medicinal ingredient in ZOMIG tablets. Therefore, patients with rare hereditary problems of galactose intolerance (the Lapp lactase deficiency or glucose-galactose malabsorption) should not take ZOMIG tablets.

Psychomotor Effect: Although ZOMIG did not interfere with psychomotor performance in healthy volunteers, some patients in clinical trials experienced sedation with ZOMIG. Patients
should thus be advised to avoid driving a car or operating hazardous machinery until they are reasonably certain that ZOMIG does not affect them adversely.

**Medication Overuse Headache:** Prolonged use of any type of painkiller for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained, and treatment should be discontinued. The diagnosis of medication overuse headache (MOH) should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of headache medications.

**Cardiovascular**

**Risk of Myocardial Ischemia and/or Infarction and Other Adverse Cardiac Events:**

ZOMIG has been associated with transient chest and/or neck pain and tightness which may resemble angina pectoris. Following the use of other 5-HT1 agonists, in rare cases these symptoms have been identified as being the likely result of coronary vasospasm or myocardial ischemia. Rare cases of serious coronary events or arrhythmia have occurred following use of ZOMIG. In very rare cases angina pectoris has been reported.

ZOMIG should not be given to patients who have documented ischemic or vasospastic coronary artery disease (see CONTRAINDICATIONS). It is strongly recommended that ZOMIG not be given to patients in whom unrecognised coronary artery disease (CAD) is predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family history of CAD, female who is surgically or physiologically postmenopausal, or male who is over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery vasospasm is unknown. If, during the cardiovascular evaluation, the patient’s medical history or electrocardiographic investigations reveal findings indicative of or consistent with coronary artery vasospasm or myocardial ischemia, ZOMIG should not be administered (see CONTRAINDICATIONS).

These evaluations, however, may not identify every patient who has cardiac disease, and in very rare cases, serious cardiac events, such as myocardial infarction or coronary ischemia have occurred in patients without evidence of underlying cardiovascular disease.

For patients with risk factors predictive of CAD who are considered to have a satisfactory cardiovascular evaluation, the first dose of ZOMIG should be administered in the setting of a physician’s office or similar medically staffed and equipped facility. Because cardiac ischemia can occur in the absence of clinical symptoms, consideration should be given to obtaining electrocardiograms in patients with risk factors during the interval immediately following ZOMIG administration on the first occasion of use. However, an absence of drug-induced cardiovascular effects on the occasion of the initial dose does not preclude the possibility of such effects occurring with subsequent administrations.
Intermittent long-term users of ZOMIG, who have or acquire risk factors predictive of CAD, as described above, should receive periodic interval cardiovascular evaluations over the course of treatment.

If symptoms consistent with angina occur after the use of ZOMIG, ECG evaluation should be carried out to look for ischemic changes.

*The systematic approach described above is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be inadvertently exposed to ZOMIG.*

As with other 5HT\textsubscript{1B/1D} agonists, atypical sensations over the precordium have been reported after the administration of zolmitriptan. Where such symptoms are thought to indicate ischemic heart disease, no further doses of zolmitriptan should be given and appropriate evaluation carried out.

Discomfort in the chest, neck, throat and jaw (including pain, pressure, heaviness and tightness) has been reported after administration of ZOMIG. Because 5-HT\textsubscript{1} agonists may cause coronary vasospasm, patients who experience signs or symptoms suggestive of angina following ZOMIG should be evaluated for the presence of CAD or a predisposition to variant angina before receiving additional doses, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur. Similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud’s syndrome following ZOMIG administration should be evaluated for atherosclerosis or predisposition to vasospasm (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS).

**Cardiac Events and Fatalities Associated with 5-HT\textsubscript{1} Agonists**

As with other triptans, zolmitriptan may cause coronary artery vasospasm. Serious adverse cardiac events, including acute myocardial infarction, life-threatening disturbances of cardiac rhythm, and death have been reported within a few hours following the administration of other 5-HT\textsubscript{1} agonists. Considering the extent of use of 5-HT\textsubscript{1} agonists in patients with migraine, the incidence of these events is extremely low.

Patients with symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders should not receive ZOMIG.

**Premarketing Experience with ZOMIG**

Among the more than 2,500 patients with migraine who participated in premarketing controlled clinical trials of ZOMIG conventional tablets, no deaths or serious cardiac events were reported. In premarketing controlled clinical trials of ZOMIG Nasal Spray, more than 1300 patients participated and there were no deaths or serious cardiac events to report.

**Postmarketing Experience with ZOMIG**

Serious cardiovascular events have been reported in association with the use of ZOMIG. The uncontrolled nature of postmarketing surveillance, however, makes it impossible to determine definitively the proportion of reported cases that were actually caused by ZOMIG or to reliably assess causation in individual cases.
Cerebrovascular Events and Fatalities With 5-HT₁ Agonists

Migraineurs may be at risk of certain cerebrovascular events. Cerebral haemorrhage, subarachnoid haemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with 5-HT₁ agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the agonist having been administered in the incorrect belief that the symptoms were a consequence of migraine, when they were not. Before treating migraine headaches with ZOMIG in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. If a patient does not respond to the first dose, the opportunity should be taken to review the diagnosis before a second dose is given. It should be noted that patients with migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, haemorrhage, TIA).

Special Cardiovascular Pharmacology Studies With Another 5-HT₁ Agonist

In subjects (n=10) with suspected coronary artery disease undergoing angiography, a 5-HT₁ agonist at a subcutaneous dose of 1.5 mg produced an 8% increase in aortic blood pressure, an 18% increase in pulmonary artery blood pressure, and an 8% increase in systemic vascular resistance. In addition, mild chest pain or tightness was reported by four subjects. Clinically significant increases in blood pressure were experienced by three of the subjects (two of whom also had chest pain/discomfort). Diagnostic angiogram results revealed that 9 subjects had normal coronary arteries and 1 had insignificant coronary artery disease.

In an additional study with this same drug, migraine patients (n=35) free of cardiovascular disease were subjected to assessments of myocardial perfusion by positron emission tomography while receiving a subcutaneous 1.5 mg dose in the absence of a migraine attack. Reduced coronary vasodilatory reserve (~10%), increased coronary resistance (~20%), and decreased hyperaemic myocardial blood flow (~10%) were noted. The relevance of these findings to the use of the recommended oral dose of this 5-HT₁ agonist is not known.

Similar studies have not been done with ZOMIG. However, owing to the common pharmacodynamic actions of 5-HT₁ agonists, the possibility of cardiovascular effects of the nature described above should be considered for any agent of this pharmacological class.

Other Vasospasm-Related Events: 5-HT₁ agonists may cause vasospastic reactions other than coronary artery vasospasm. Peripheral vascular ischemia has been reported with 5-HT₁ agonists (see ADVERSE REACTIONS). Very rare reports of splenic infarction and gastrointestinal ischemic events including ischemic colitis, gastrointestinal infarction or necrosis, which may present as bloody diarrhea or abdominal pain, have been received.

Increased Blood Pressure: Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions in patients receiving other 5-HT₁ agonists with and without a history of hypertension. Very rarely these increases in blood pressure have been associated with significant clinical events. Isolated reports of chest pain, pulmonary edema, coronary vasospasm, transient cerebral ischemia, angina and subarachnoid hemorrhage have been received (see CONTRAINDICATIONS). In patients with controlled hypertension, ZOMIG should be administered with caution, as transient increases in blood pressure and peripheral vascular resistance have been observed in a small portion of patients.
In pharmacodynamic studies, an increase of 1 and 5 mm Hg in the systolic and diastolic blood pressure, respectively, was seen in volunteers with 5 mg ZOMIG. In the headache trials, vital signs were measured only in a small, single-centre inpatient study, and no effect on blood pressure was seen. In a study of patients with moderate to severe liver disease, 7 of 27 patients experienced 20 to 80 mm Hg elevations in systolic or diastolic blood pressure after a 10 mg ZOMIG dose. Significant elevations in systemic blood pressure, including hypertensive crisis, have been reported on rare occasions in patients with and without a history of hypertension who received 5-HT1 agonists. ZOMIG is contraindicated in patients with uncontrolled or severe hypertension (see CONTRAINDICATIONS).

**Dependence**

The abuse potential of ZOMIG has not been assessed in clinical trials.

**Endocrine and Metabolism**

**Phenylketonuria:** Patients with phenylketonuria should be informed that ZOMIG RAPIMELT orally dispersible tablets contain phenylalanine (a component of aspartame). Each orally dispersible tablet contains 2.81 mg of phenylalanine.

**Hepatic**

ZOMIG should be administered with caution to patients with moderate or severe hepatic impairment, using a dose lower than 2.5 mg (see ACTION AND CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

**Immune**

Rare hypersensitivity (anaphylaxis/anaphylactoid) reactions may occur in patients receiving 5-HT1 agonists such as ZOMIG. Such reactions can be life threatening or fatal. In general, hypersensitivity reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens. Owing to the possibility of cross-reactive hypersensitivity reactions, ZOMIG should not be used in patients having a history of hypersensitivity to chemically-related 5-HT1 receptor agonists (see Adverse Events in PRECAUTIONS ADVERSE REACTIONS).

**Neurologic**

Care should be taken to exclude other potentially serious neurologic conditions before treating headache in patients not previously diagnosed with migraine or who experience a headache that is atypical for them. There have been rare reports where patients received 5-HT1 agonists for severe headache that were subsequently shown to have been secondary to an evolving neurological lesion. For newly diagnosed patients or patients presenting with atypical symptoms, the diagnosis of migraine should be reconsidered if no response is seen after the first dose of ZOMIG.

**Seizures:** Caution should be observed if ZOMIG is to be used in patients with a history of epilepsy or structural brain lesions, which lower the convulsion threshold.
Serotonin toxicity / Serotonin syndrome

Serotonin toxicity, also known as serotonin syndrome, is a potentially life-threatening condition and has been reported with triptans, including ZOMIG, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs). Serotonin toxicity is characterised by neuromuscular excitation, autonomic stimulation (e.g. tachycardia, flushing) and altered mental state (e.g. anxiety, agitation, hypomania). In accordance with the Hunter Criteria, serotonin toxicity diagnosis is likely when, in the presence of at least one serotonergic agent, one of the following is observed:

- Spontaneous clonus
- Inducible clonus or ocular clonus with agitation or diaphoresis
- Tremor and hyperreflexia
- Hypertonia and body temperature >38°C and ocular clonus or inducible clonus
- If concomitant treatment with ZOMIG and SSRIs (e.g., fluoxetine, paroxetine, sertraline) or SNRIs (e.g., venlafaxine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see DRUG INTERACTIONS). If serotonin toxicity is suspected, discontinuation of the serotonergic agents should be considered.

Ophthalmologic

Binding to Melanin-Containing Tissues: When pigmented rats were given a single oral dose of 10 mg/kg of radiolabelled zolmitriptan, the radioactivity in the eye after 7 days, the latest time point examined, was still 75% of the values measured after 4 hours. This suggests that zolmitriptan and/or its metabolites may bind to the melanin of the eye. Because there could be accumulation in melanin rich tissues over time, it raises the possibility that zolmitriptan could cause toxicity in these tissues after extended use. However, no effects on the retina related to treatment with zolmitriptan were noted in any of the toxicity studies. No systematic monitoring of ophthalmologic function was undertaken in clinical trials, and no specific recommendations for ophthalmologic monitoring are offered, however, prescribers should be aware of the possibility of long-term ophthalmologic effects.

Preclinical Toxicology

Carcinogenicity: Carcinogenicity studies by oral gavage were carried out in rats and mice at doses up to 400 mg/kg/day. In mice the total exposure at the highest dose level was approximately 800 times that seen after a single 10 mg dose in humans and there was no effect on tumour type or incidence. In male rats at this dose level, where total exposure was approximately 3000 times that seen after a single 10 mg dose in humans, there was an increase in the incidence of thyroid follicular hyperplasia and benign adenomata. This has been shown to be due to an increase in thyroxine clearance caused by zolmitriptan at this dose level with a resultant chronic stimulation of the thyroid. There was no effect on tumour profile at the dose level of 100 mg/kg/day that gave an exposure multiple of approximately 800.

Mutagenicity: Zolmitriptan was mutagenic in an Ames test, in 2 of 5 strains of Salmonella typhimurium tested, in the presence of, but not in the absence of, metabolic activation. It was not
mutagenic in an in vitro mammalian gene cell mutation (CHO/HGPRT) assay. The nasal spray formulation was not mutagenic in two further Ames tests. Zolmitriptan was clastogenic in an in vitro human lymphocyte assay both in the absence of and the presence of metabolic activation. Zolmitriptan was not clastogenic in an in vivo mouse micronucleus assay. In three rat bone marrow micronucleus assays with the nasal spray formulation, the results overall were negative. In a mouse bone marrow micronucleus assay with the nasal spray formulation, there were sporadic increases in micronucleus erythrocytes, but the results were equivocal. Zolmitriptan was not genotoxic in an unscheduled DNA synthesis study.

**Special Populations**

**Pregnant Women:** Reproductive studies in male and female rats, at dose levels limited by toxicity, revealed no effect on fertility or reproduction.

Reproduction studies in rats and rabbits dosed during the period of organogenesis have been performed at levels limited by maternal toxicity. In rats dosed orally by gavage at 1200 mg/kg/day, giving a total exposure 3000 - 5000 times that seen following a single 10 mg dose in humans, there was a slight increase in early resorptions but no effect on fetal malformations. At a dose of 400 mg/kg/day in rats, an exposure multiple of approximately 1100, there were no effects of any kind on the fetus. The maximum achieved dose in rabbits was 30 mg/kg/day that gave a total exposure 30 - 40 times that seen following a single 10 mg dose in humans and there were no fetal effects.

The safety of ZOMIG for use during human pregnancy has not been established. ZOMIG should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Nursing Women:** It is not known whether zolmitriptan and/or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when considering the administration of ZOMIG to nursing women. Lactating rats dosed with zolmitriptan had milk levels equivalent to maternal plasma levels at 1 hour and 4 times higher than plasma levels at 4 hours.

**Pediatrics (<12 years of age):** The safety and efficacy of ZOMIG have not been studied in children under 12 years of age. Use of the drug in this age group is, therefore, not recommended.

**Adolescents (12-17 years of age):** Systemic exposure to the parent compound does not differ significantly between adolescents and adults, however exposure to the active metabolite is greater in adolescents (see ACTION AND CLINICAL PHARMACOLOGY). The safety and efficacy of ZOMIG have not been established in patients 12-17 years of age. The use of ZOMIG in adolescents is, therefore, not recommended.

In a single randomized placebo-controlled study of 696 adolescent migraineurs (aged 12-17 years), the efficacy of ZOMIG tablets (2.5, 5 and 10 mg) was not established (see ADVERSE REACTIONS, Special Populations).

**Geriatrics (> 65 years of age):** The safety and efficacy of ZOMIG have not been studied in individuals over 65 years of age. The risk of adverse reactions to this drug may be greater in
elderly patients as they are more likely to have decreased hepatic function, be at higher risk for CAD, and experience blood pressure increases that may be more pronounced. Clinical studies did not include patients over 65 year of age. Its use in this age group is, therefore, not recommended.

Special Disease Conditions:
ZOMIG should be administered with caution to patients with diseases that may alter the absorption, metabolism, or excretion of drugs, such as impaired hepatic function (see WARNINGS AND PRECAUTIONS, Hepatic).

Monitoring and Laboratory Tests
Zolmitriptan is not known to interfere with commonly employed clinical laboratory tests.

ADVERSE REACTIONS
Serious cardiac events, including some that have been fatal, have occurred following the use of 5-HT$_1$ agonists. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Events reported have included coronary artery vasospasm, transient myocardial ischemia, angina pectoris, myocardial infarction, ventricular tachycardia, and ventricular fibrillation (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS, General).

Clinical Trial Adverse Drug Reactions
Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Frequencies of adverse events are reported as follows:

Very common (≥10%)
Common (≥1% - <10%)
Uncommon (≥0.1% - <1%)
Rare (≥0.01% - <0.1%)
Very Rare (<0.01%)

Experience in Controlled Clinical Trials with ZOMIG (zolmitriptan)
Typical 5-HT$_1$ Agonist Adverse Reactions: As with other 5-HT$_1$ agonists, ZOMIG has been associated with sensations of heaviness, pressure, tightness or pain which may be intense. These may occur in any part of the body including the chest, throat, neck, jaw and upper limb. In very rare cases, as with other 5-HT$_1$ agonists, angina pectoris and myocardial infarction have been reported.
Transient increases in systemic blood pressure, have been reported in patients, with and without a history of hypertension. Very rarely these increases in blood pressure have been associated with significant clinical events. Isolated reports of chest pain, pulmonary edema, coronary vasospasm, transient cerebral ischemia, angina and subarachnoid hemorrhage have been received (see WARNINGS AND PRECAUTIONS, Cardiovascular, Increased Blood Pressure).

There have been rare reports of hypersensitivity reactions including urticaria and angioedema (see WARNINGS AND PRECAUTIONS, Immune).

EXPERIENCE WITH ZOMIG CONVENTIONAL TABLET (zolmitriptan)

Acute Safety: In placebo-controlled migraine trials, 1,673 patients received at least one dose of ZOMIG. The following table (Table 1) lists adverse events that occurred in five placebo-controlled clinical trials in migraine patients. Events that occurred at an incidence of 1% or more in any one of the ZOMIG 1 mg, 2.5 mg or 5 mg dose groups and that occurred at a higher incidence than in the placebo group are included. The events cited reflect experience gained under closely monitored conditions in clinical trials, in a highly selected patient population. In actual clinical practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behaviour, and the kinds of patients treated may differ.

Several of the adverse events appear dose related, notably paresthesia, sensation of heaviness or tightness in chest, neck, jaw and throat, dizziness, somnolence, and possibly asthenia and nausea.

Table 1  Treatment Emergent Adverse Events in Five Single-Attack Placebo-Controlled Migraine Trials, Reported by ≥1% Patients Treated With ZOMIG

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Zomig 1 mg</th>
<th>Zomig 2.5 mg</th>
<th>Zomig 5 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>401</td>
<td>163</td>
<td>498</td>
<td>1012</td>
</tr>
</tbody>
</table>

% incidence

Symptoms of potential cardiac origin:

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Neck/Throat/Jaw Sensations*</td>
<td>3.0</td>
<td>6.1</td>
<td>7.0</td>
<td>10.9</td>
</tr>
<tr>
<td>Chest/Thorax Sensations*</td>
<td>1.2</td>
<td>1.8</td>
<td>3.4</td>
<td>3.8</td>
</tr>
<tr>
<td>Upper Limb Sensations*</td>
<td>0.5</td>
<td>2.4</td>
<td>4.2</td>
<td>4.1</td>
</tr>
<tr>
<td>Palpitations</td>
<td>0.7</td>
<td>0</td>
<td>0.2</td>
<td>2.2</td>
</tr>
</tbody>
</table>

Other Body Systems:

Neurological:

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dizziness</td>
<td>4.0</td>
<td>5.5</td>
<td>8.4</td>
<td>9.5</td>
</tr>
<tr>
<td>Nervousness</td>
<td>0.2</td>
<td>0</td>
<td>1.4</td>
<td>0.7</td>
</tr>
<tr>
<td>Somnolence</td>
<td>3.0</td>
<td>4.9</td>
<td>6.0</td>
<td>7.7</td>
</tr>
<tr>
<td>Thinking Abnormal</td>
<td>0.5</td>
<td>0</td>
<td>1.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Tremor</td>
<td>0.7</td>
<td>0.6</td>
<td>1.0</td>
<td>0.7</td>
</tr>
<tr>
<td>Vertigo</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1.5</td>
</tr>
<tr>
<td>Hyperesthesia</td>
<td>0</td>
<td>0</td>
<td>0.6</td>
<td>1.1</td>
</tr>
</tbody>
</table>

Digestive:

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>0.5</td>
<td>0.6</td>
<td>1.0</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>Zomig 1 mg</td>
<td>Zomig 2.5 mg</td>
<td>Zomig 5 mg</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------</td>
<td>------------</td>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>Number of patients</td>
<td>401</td>
<td>163</td>
<td>498</td>
<td>1012</td>
</tr>
<tr>
<td>% incidence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td>1.7</td>
<td>4.9</td>
<td>3.2</td>
<td>3.2</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>0.5</td>
<td>3.1</td>
<td>1.6</td>
<td>1.0</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1.8</td>
</tr>
<tr>
<td>Nausea</td>
<td>3.7</td>
<td>3.7</td>
<td>9.0</td>
<td>6.2</td>
</tr>
<tr>
<td>Vomit</td>
<td>2.5</td>
<td>0.6</td>
<td>1.4</td>
<td>1.5</td>
</tr>
<tr>
<td><strong>Miscellaneous:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenia</td>
<td>3.2</td>
<td>4.9</td>
<td>3.2</td>
<td>8.8</td>
</tr>
<tr>
<td>Limb Sensations (upper and lower)*</td>
<td>0.7</td>
<td>0.6</td>
<td>0.4</td>
<td>1.6</td>
</tr>
<tr>
<td>Limb Sensations (lower)*</td>
<td>0.7</td>
<td>1.2</td>
<td>0.4</td>
<td>1.8</td>
</tr>
<tr>
<td>Sensations - location unspecified*</td>
<td>5.2</td>
<td>4.9</td>
<td>5.8</td>
<td>9.2</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>1.7</td>
<td>1.2</td>
<td>0.6</td>
<td>1.3</td>
</tr>
<tr>
<td>Reaction Aggravated</td>
<td>1.0</td>
<td>1.2</td>
<td>1.0</td>
<td>0.7</td>
</tr>
<tr>
<td>Head/face Sensations*</td>
<td>1.7</td>
<td>6.7</td>
<td>8.6</td>
<td>10.9</td>
</tr>
<tr>
<td>Myalgia</td>
<td>0.2</td>
<td>0</td>
<td>0.2</td>
<td>1.3</td>
</tr>
<tr>
<td>Myasthenia</td>
<td>0.2</td>
<td>0</td>
<td>0.6</td>
<td>1.9</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>0.2</td>
<td>0.6</td>
<td>0.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>0.2</td>
<td>1.2</td>
<td>1.2</td>
<td>0.9</td>
</tr>
<tr>
<td>Sweating</td>
<td>1.2</td>
<td>0</td>
<td>1.6</td>
<td>2.5</td>
</tr>
<tr>
<td>Taste Perversion</td>
<td>0.5</td>
<td>2.5</td>
<td>0.6</td>
<td>0.7</td>
</tr>
</tbody>
</table>

* The term sensation encompasses adverse events described as pain, discomfort, pressure, heaviness, tightness, heat/burning sensations, tingling and paresthesia.

ZOMIG is generally well tolerated. Across all doses, most adverse events were mild to moderate in severity as well as transient and self-limiting. The incidence of adverse events in controlled clinical trials was not affected by gender, weight, or age of patients; use of prophylactic medications; or presence of aura. There were insufficient data to assess the impact of race on the incidence of adverse events.

**Long Term Safety:** In a long-term open label study in which patients were allowed to treat multiple migraine attacks for up to one year, 8% (167 of 2,058) of patients withdrew from the study due to an adverse experience. In this study, migraine headaches could be treated with either a single 5 mg dose of ZOMIG, or an initial 5 mg dose followed by a second 5 mg dose if necessary (5+5 mg). The most common adverse events (defined as occurring at an incidence of at least 5%) recorded for the 5 mg and 5+5 mg doses, respectively, comprised, in descending order of frequency: neck/throat sensations* (16%, 15%), head/face sensations* (15%, 14%), asthenia (14%, 14%), sensations* location unspecified (12%, 11%), limb sensations* (11%, 11%), nausea (12%, 8%), dizziness (11%, 9%), somnolence (10%, 10%), chest/thorax sensations* (7%, 7%), dry mouth (4%, 5%), and hyperesthesia (5%, 4%). Due to the lack of a placebo arm in this study, the role of ZOMIG in causation cannot be reliably determined. (*See footnote for Table 1). The long term safety of a 2.5 mg dose was not assessed in this study.
**Other Events**: The frequencies of less commonly reported adverse clinical events are presented below. Because the reports include events observed in open and uncontrolled studies, the role of ZOMIG in their causation cannot be reliably determined. Furthermore, variability associated with adverse event reporting, the terminology used to describe adverse events, etc., limit the value of the quantitative frequency estimates provided. Event frequencies are calculated as the number of patients who used ZOMIG (n=4,027) and reported an event divided by the total number of patients exposed to ZOMIG. All reported events are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Events are further classified within body system categories and enumerated in order of decreasing frequency.

**Atypical sensation**: Uncommon was hyperesthesia.

**General**: Uncommon were allergy reaction, chills, facial edema, fever, malaise and photosensitivity.

**Cardiovascular**: Uncommon were arrhythmias, hypertension and syncope. Rare were bradycardia, extrasystoles, postural hypotension, QT prolongation, and thrombophlebitis. Rare reports of tachycardia, palpitations and transient increases in systemic blood pressure in patients with or without a history of hypertension (see WARNINGS AND PRECAUTIONS, Cardiovascular, Increased Blood Pressure).

**Digestive**: Uncommon were increased appetite, tongue edema, esophagitis, gastroenteritis, liver function abnormality and thirst. Rare were anorexia, constipation, gastritis, hematemesis, pancreatitis, melena and ulcer.

**Hemic**: Uncommon was ecchymosis. Rare were cyanosis, thrombocytopenia, eosinophilia and leucopenia.

**Metabolic**: Uncommon was edema. Rare were hyperglycemia and alkaline phosphatase increased.

**Musculoskeletal**: Uncommon were back pain, leg cramps and tenosynovitis. Rare were arthritis, tetany and twitching.

**Neurological**: Uncommon were agitation, anxiety, depression, emotional lability and insomnia. Rare were akathisia, amnesia, apathy, ataxia, dystonia, euphoria, hallucinations, cerebral ischemia, hyperkinesia, hypotonia, hypertonia, irritability and headache.

**Respiratory**: Uncommon were bronchitis, bronchospasm, epistaxis, hiccup, laryngitis and yawn. Rare were apnea and voice alteration.

**Skin**: Uncommon were pruritus, and rash. Rare reports were urticaria and angioedema.

**Special Senses**: Uncommon were dry eye, eye pain, hyperacusis, ear pain, parosmia, and tinnitus. Rare were diplopia and lacrimation.

**Urogenital**: Uncommon were hematuria, cystitis, polyuria, urinary frequency and urinary urgency. Rare were miscarriage and dysmenorrhea.
EXPERIENCE IN CONTROLLED CLINICAL TRIALS WITH ZOMIG RAPIMELT (zolmitriptan)

**Acute Safety:** In an international, placebo-controlled, double-blind trial to evaluate the efficacy and tolerability of ZOMIG RAPIMELT 2.5 mg in the acute treatment of adult patients with migraine, 231 patients received at least one dose of ZOMIG RAPIMELT. Most of the adverse events were of mild or moderate intensity, and no patients withdrew from the trial because of adverse events. The types of adverse events reported were consistent with known effects of this class of compound (5-HT1B/1D) and were similar to those reported with the ZOMIG conventional tablet. The most frequently reported adverse events (>2%) for ZOMIG RAPIMELT 2.5 mg versus placebo, respectively, were asthenia (3% vs. 1%), tightness (3% vs. <1%), somnolence (3% vs. 2%), dizziness (3% vs. 1%), paresthesia (3% vs. 2%), hyperesthesia (2% vs. 0%), pharyngitis (2% vs. 0%), and nausea (2% vs. 1%).

EXPERIENCE IN CONTROLLED CLINICAL TRIALS WITH ZOMIG NASAL SPRAY (zolmitriptan)

**Acute Safety:** Among 1,383 patients treating 3,398 attacks with zolmitriptan nasal spray in a blinded placebo-controlled trial, there was a low withdrawal rate related to adverse events: 5 mg (1.3%), 2.5 mg (0%), 1 mg (0.8%) and placebo (0.4%). None of the withdrawals were due to a serious event. One patient was withdrawn due to abnormal ECG changes from baseline that were incidentally found 23 days after the last dose of ZOMIG Nasal Spray. The most common adverse events in clinical trials for ZOMIG Nasal Spray were: unusual taste, paresthesia, hyperesthesia, and dizziness. Table 2 lists the adverse events that occurred in ≥ 1% of the 1,383 patients in the 2.5 mg tablet, placebo, 1 mg, 2.5 mg and 5 mg nasal spray dose groups of the controlled clinical trial.

Table 2  Adverse events in a single placebo-controlled study, with an incidence of ≥1% of patients in any ZOMIG Nasal Spray treatment group by body system

<table>
<thead>
<tr>
<th>Body System and Adverse event (COSTART defined)</th>
<th>Tablet* 2.5mg (N=233)</th>
<th>Placebo* 1.0 mg (N=228)</th>
<th>ZOMIG Nasal Spray 2.5 mg (N=238)</th>
<th>ZOMIG Nasal Spray 5.0 mg (N=224)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYMPTOMS OF POTENTIAL CARDIAC ORIGIN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain Throat</td>
<td>1.3%</td>
<td>0.4%</td>
<td>0.0%</td>
<td>2.7%</td>
</tr>
<tr>
<td>Pressure Throat</td>
<td>0.9%</td>
<td>0.0%</td>
<td>0.4%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Tightness Throat</td>
<td>1.3%</td>
<td>0.9%</td>
<td>1.3%</td>
<td>0.4%</td>
</tr>
<tr>
<td>Tightness Neck</td>
<td>1.3%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Tightness Chest</td>
<td>1.3%</td>
<td>0.0%</td>
<td>0.8%</td>
<td>0.4%</td>
</tr>
<tr>
<td>Palpitation</td>
<td>1.3%</td>
<td>0.4%</td>
<td>1.7%</td>
<td>1.3%</td>
</tr>
<tr>
<td>BODY / ABDOMEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain Abdominal</td>
<td>0.4%</td>
<td>0.9%</td>
<td>1.7%</td>
<td>1.3%</td>
</tr>
<tr>
<td>BODY / GENERAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenia</td>
<td>2.1%</td>
<td>0.4%</td>
<td>0.4%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Heaviness Other</td>
<td>1.7%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Pain Local Specific</td>
<td>0.0%</td>
<td>0.4%</td>
<td>1.7%</td>
<td>0.9%</td>
</tr>
</tbody>
</table>
### Percentage of Patients

<table>
<thead>
<tr>
<th>Body System and Adverse event (COSTART defined)(^a)</th>
<th>Tablet(^b) (N=233)</th>
<th>Placebo(^c) (N=228)</th>
<th>ZOMIG Nasal Spray 1.0 mg (N=238)</th>
<th>ZOMIG Nasal Spray 2.5 mg (N=224)</th>
<th>ZOMIG Nasal Spray 5.0 mg (N=236)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reaction Aggravation(^c)</td>
<td>0.0%</td>
<td>2.2%</td>
<td>0.4%</td>
<td>0.9%</td>
<td>2.1%</td>
</tr>
<tr>
<td><strong>DIGESTIVE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry Mouth</td>
<td>1.3%</td>
<td>0.0%</td>
<td>1.7%</td>
<td>2.2%</td>
<td>1.3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>1.3%</td>
<td>0.9%</td>
<td>1.3%</td>
<td>0.9%</td>
<td>1.7%</td>
</tr>
<tr>
<td><strong>NERVOUS SYSTEM / CNS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>1.7%</td>
<td>3.5%</td>
<td>2.9%</td>
<td>0.4%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>0.0%</td>
<td>0.0%</td>
<td>1.3%</td>
<td>1.3%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Somnolence</td>
<td>0.4%</td>
<td>1.3%</td>
<td>0.8%</td>
<td>0.4%</td>
<td>1.7%</td>
</tr>
<tr>
<td><strong>NERVOUS SYSTEM / GENERAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperesthesia</td>
<td>0.9%</td>
<td>0.0%</td>
<td>0.8%</td>
<td>0.4%</td>
<td>2.1%</td>
</tr>
<tr>
<td>Hypoesthesia</td>
<td>1.3%</td>
<td>0.4%</td>
<td>0.4%</td>
<td>0.9%</td>
<td>0.8%</td>
</tr>
<tr>
<td><strong>NERVOUS SYSTEM / PNS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paresthesia</td>
<td>4.3%</td>
<td>3.9%</td>
<td>4.2%</td>
<td>3.1%</td>
<td>5.9%</td>
</tr>
<tr>
<td>Sensation Warm</td>
<td>2.1%</td>
<td>2.2%</td>
<td>0.4%</td>
<td>0.9%</td>
<td>0.0%</td>
</tr>
<tr>
<td><strong>RESPIRATORY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disorder or Discomfort of Nasal Cavity</td>
<td>0.9%</td>
<td>1.3%</td>
<td>2.1%</td>
<td>0.9%</td>
<td>1.3%</td>
</tr>
<tr>
<td><strong>SPECIAL SENSES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unusual Taste</td>
<td>1.3%</td>
<td>3.1%</td>
<td>7.6%</td>
<td>13.4%</td>
<td>16.9%</td>
</tr>
</tbody>
</table>

\(^a\) The Patient may have had more than 1 adverse event.  
\(^b\) The placebo treatment group included patients treated with placebo nasal spray and oral placebo.  
\(^c\) Events reported under this term includes increased nausea and increased headache.  
\(^*\) The incidences reported in this table are from one single placebo-controlled study. The treatment-emergent adverse events in five single-attack placebo-controlled migraine trials, reported by ≥1% patients treated with ZOMIG 1 mg, 2.5 mg and 5 mg tablets are listed in Table 1.

**Local Adverse Reactions:** Among 922 patients using an active zolmitriptan nasal spray to treat 2311 attacks in the controlled clinical study, approximately 3% noted local irritation or soreness at the site of administration. Adverse events of any kind, perceived in the nasopharynx (which may include systemic effects of triptans) were severe in about 1% of patients and approximately 60% resolved in 1 hour.

The adverse experience profile seen with ZOMIG Nasal Spray is similar to that seen with ZOMIG conventional tablets and ZOMIG RAPIMELT tablets, except for localized adverse events related to nasal dosing.

**Overall Results of Clinical Trials**

In a pool of 51 placebo-controlled and open labelled studies the above adverse events were reported at the described frequencies, with the exception of the following adverse events which were reported at a greater frequency. In total 17,301 patients with migraine were treated with ZOMIG, ZOMIG RAPIMELT or ZOMIG Nasal Spray. Events are classified within body system categories and enumerated in order of decreasing frequency.
Cardiac Disorders: Uncommon was tachycardia.

Gastrointestinal Disorders: Common was dysphagia, vomiting and abdominal pain.

Nervous System Disorders: Common was headache.

Respiratory: Common was epistaxis for ZOMIG Nasal Spray only.

Vascular Disorders: Uncommon was transient increases in systemic blood pressure.

Sensations of heaviness, tightness, pain or pressure in the throat, neck, limbs or chest were common and consistent with those observed in Tables 1 and 2.

Adverse Drug Reactions in Special Population

Adolescents (12-17 years of age)

Table 3 lists the adverse events observed in a single randomized placebo-controlled study of 696 adolescent migraineurs aged 12-17 years (see WARNINGS AND PRECAUTIONS, Special Populations).

Table 3  Adverse events in a single placebo-controlled adolescent study, reported by ≥1% of patients treated with ZOMIG

<table>
<thead>
<tr>
<th>Body System and Adverse Event (COSTART term)</th>
<th>Placebo (N=176)</th>
<th>2.5 mg (N=171)</th>
<th>5 mg (N=174)</th>
<th>10 mg (N=178)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasodilatation</td>
<td>0.6</td>
<td>0</td>
<td>2.9</td>
<td>3.9</td>
</tr>
<tr>
<td>Palpitation</td>
<td>0</td>
<td>0</td>
<td>1.1</td>
<td>0</td>
</tr>
<tr>
<td><strong>Whole Body</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tightness</td>
<td>1.1</td>
<td>2.9</td>
<td>5.7</td>
<td>11.2</td>
</tr>
<tr>
<td>Asthenia</td>
<td>1.1</td>
<td>1.8</td>
<td>1.1</td>
<td>5.1</td>
</tr>
<tr>
<td>Pain</td>
<td>0</td>
<td>1.8</td>
<td>1.7</td>
<td>5.1</td>
</tr>
<tr>
<td>Neck Pain</td>
<td>0</td>
<td>0.6</td>
<td>1.7</td>
<td>3.4</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>0.6</td>
<td>1.2</td>
<td>0</td>
<td>1.7</td>
</tr>
<tr>
<td>Headache</td>
<td>0</td>
<td>1.2</td>
<td>2.9</td>
<td>1.1</td>
</tr>
<tr>
<td>Malaise</td>
<td>0</td>
<td>0</td>
<td>2.3</td>
<td>0.6</td>
</tr>
<tr>
<td>Pressure</td>
<td>0</td>
<td>1.8</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Stiffness</td>
<td>0</td>
<td>0</td>
<td>0.6</td>
<td>2.8</td>
</tr>
<tr>
<td>Heaviness</td>
<td>1.1</td>
<td>0.6</td>
<td>0</td>
<td>1.1</td>
</tr>
<tr>
<td><strong>Digestive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>1.1</td>
<td>5.8</td>
<td>2.9</td>
<td>7.9</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1.1</td>
<td>0.6</td>
<td>1.7</td>
<td>4.5</td>
</tr>
<tr>
<td>Dry Mouth</td>
<td>0.6</td>
<td>1.8</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td><strong>Nervous System</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body System and Adverse Event (COSTART term)</td>
<td>Placebo (N=176)</td>
<td>2.5 mg (N=171)</td>
<td>5 mg (N=174)</td>
<td>10 mg (N=178)</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-----------------</td>
<td>---------------</td>
<td>--------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2.3</td>
<td>4.7</td>
<td>4.6</td>
<td>9.0</td>
</tr>
<tr>
<td>Paresthesia</td>
<td>0</td>
<td>1.8</td>
<td>4.6</td>
<td>6.2</td>
</tr>
<tr>
<td>Somnolence</td>
<td>1.7</td>
<td>1.2</td>
<td>1.7</td>
<td>2.8</td>
</tr>
<tr>
<td>Hypertonia</td>
<td>0</td>
<td>0.6</td>
<td>1.7</td>
<td>1.1</td>
</tr>
<tr>
<td>Internasal Paresthesia</td>
<td>0</td>
<td>2.3</td>
<td>0.6</td>
<td>0</td>
</tr>
<tr>
<td>Tremor</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1.7</td>
</tr>
<tr>
<td>Hyperesthesia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1.1</td>
</tr>
<tr>
<td><strong>Respiratory System</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>0.6</td>
<td>2.9</td>
<td>2.3</td>
<td>1.7</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>0.6</td>
<td>0</td>
<td>1.1</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Musculoskeletal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>0</td>
<td>0</td>
<td>1.1</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Skin and Appendages</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweating</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1.7</td>
</tr>
<tr>
<td><strong>Special Senses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye Pain</td>
<td>0</td>
<td>0.6</td>
<td>1.1</td>
<td>0.6</td>
</tr>
<tr>
<td>Amblyopia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1.1</td>
</tr>
</tbody>
</table>

**Post-Market Adverse Drug Reactions**

In addition to the adverse experiences reported during clinical testing of ZOMIG, the following adverse experiences have been reported in patients receiving marketed ZOMIG from worldwide use since approval. There are insufficient data to support an estimate of their incidence or to establish causality.

Serious adverse events have occurred during post-marketing surveillance following the use of ZOMIG oral tablets. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Events reported have included coronary artery vasospasm, transient myocardial ischemia, angina pectoris and myocardial infarction (see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS).

Post-market reports show that dysphagia has been reported commonly when using ZOMIG.

As with other 5-HT\textsubscript{1B/1D} agonists, there have been very rare reports of anaphylaxis or anaphylactoid reactions and gastrointestinal ischemic events including ischemic colitis, gastrointestinal infarction, splenic infarction, or necrosis, which may present as bloody diarrhea or abdominal pain.

Post-marketing experience with other triptans include a limited number of reports that describe pediatric (under 12 years of age) and adolescent (12 - 17 years of age) patients who have experienced clinically serious adverse events that are similar in nature to those reported as rare occurrences in adults.
DRUG INTERACTIONS

Drug-Drug Interactions

Ergot-Containing Drugs: Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis for these effects being additive, the use of ergot-containing or ergot-type medications (like dihydroergotamine or methysergide and zolmitriptan) within 24 hours of each other is contraindicated (see CONTRAINDICATIONS).

Other 5-HT\textsubscript{1} Agonists: The administration of ZOMIG with other 5-HT\textsubscript{1} agonists has not been evaluated in migraine patients. As an increased risk of coronary vasospasm is a theoretical possibility with co-administration of 5-HT\textsubscript{1} agonists, use of these drugs within 24 hours of each other is contraindicated (see CONTRAINDICATIONS).

All drug interaction studies with drugs listed below were performed in healthy volunteers using a single 10 mg dose of ZOMIG and a single dose of the other drug, except where otherwise noted.

MAO Inhibitors: In a limited number of subjects, following one week administration of 150 mg b.i.d. moclobemide, a specific MAO-A inhibitor, there was an increase of approximately 26% in both AUC and C\textsubscript{max} for zolmitriptan and a 3-fold increase in the AUC and C\textsubscript{max} of the active metabolite N-desmethylzolmitriptan. Administration of selegiline, a selective MAO-B inhibitor, at a dose of 10 mg/day for one week, had no effect on the pharmacokinetic parameters of zolmitriptan and the active metabolite N-desmethylzolmitriptan. The specificity of selegiline diminishes with higher doses and varies between patients. Therefore, co-administration of zolmitriptan in patients taking MAO inhibitors is contraindicated (see CONTRAINDICATIONS).

Cimetidine and other 1A2 Inhibitors: Following administration of cimetidine, a general P450 inhibitor, the half life and AUC of zolmitriptan and its active metabolite were approximately doubled. Patients taking cimetidine should not exceed a dose of 5 mg ZOMIG in any 24 hour period. Based on the overall interaction profile, an interaction with specific inhibitors of CYP 1A2 cannot be excluded. Therefore, the same dose reduction is recommended with compounds of this type, such as fluvoxamine and the quinolones (e.g., ciprofloxacin). Following the administration of rifampicin, no clinically relevant differences in the pharmacokinetics of zolmitriptan or its active metabolite were observed.

Oral Contraceptives: Retrospective analysis of pharmacokinetic data across studies indicated that mean plasma concentrations of zolmitriptan were generally greater in females taking oral contraceptives compared to those not taking oral contraceptives. Mean C\textsubscript{max} and AUC of zolmitriptan were found to be higher by 30% and 50%, respectively, and T\textsubscript{max} was delayed by 30 minutes in females taking oral contraceptives. The effect of ZOMIG on the pharmacokinetics of oral contraceptives has not been studied.

Propranolol: Propranolol, at a dose of 160 mg/day for 1 week increased the C\textsubscript{max} and AUC of zolmitriptan by 1.5-fold. C\textsubscript{max} and AUC of N-desmethylzolmitriptan were reduced by 30% and 15%, respectively. There were no interactive effects on blood pressure or pulse rate following administration of propranolol with zolmitriptan.

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors: Cases of life-threatening serotonin syndrome have been reported during combined use of
selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) and triptans (see WARNINGS AND PRECAUTIONS).

The pharmacokinetics and effects of ZOMIG on blood pressure were unaffected by 4-week pre-treatment with oral fluoxetine (20 mg/day). The effects of zolmitriptan on fluoxetine metabolism were not assessed.

**Acetaminophen:** After concurrent administration of single 10 mg doses of ZOMIG and 1 g acetaminophen, there was no significant effect on the pharmacokinetics of ZOMIG. ZOMIG reduced the AUC and C\text{max} of acetaminophen by 11% and 31% respectively and delayed the T\text{max} of acetaminophen by 1 hour.

**Metoclopramide:** Metoclopramide (single 10 mg dose) had no effect on the pharmacokinetics of ZOMIG or its metabolites.

**Xylometazoline:** An in vivo drug interaction study with ZOMIG Nasal Spray indicated that 1 spray (100 µL dose) of xylometazoline (0.1% w/v), a decongestant, administered 30 minutes prior to a 5 mg nasal dose of zolmitriptan did not alter the pharmacokinetics of zolmitriptan.

**Drug-Herb Interactions**

**St John’s Wort:** Undesirable effects may be more common during concomitant use of triptans and herbal preparations containing St John’s wort (Hypericum perforatum).

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**

The following general statements apply to all dosage formulations of ZOMIG.

*ZOMIG (zolmitriptan) is recommended only for the acute treatment of migraine attacks. ZOMIG should not be used prophylactically.*

The recommended adult starting dose for ZOMIG is 2.5 mg (see individual dosage forms under DOSAGE AND ADMINISTRATION, Recommended Dose and Dose Adjustment).

If the headache returns, the dose may be repeated after 2 hours. A dose should not be repeated, regardless of dosage form, within 2 hours. A total cumulative dose of 10 mg should not be exceeded in any 24 hour period.

Controlled trials have not established the effectiveness of a second dose if the initial dose is ineffective.

The safety of treating more than 3 migraine headaches with ZOMIG in a one month period remains to be established.

**Hepatic Impairment:** Patients with moderate to severe hepatic impairment have decreased clearance of zolmitriptan and significant elevation in blood pressure was observed in some patients. Use of a low dose (<2.5 mg) with blood pressure monitoring is recommended (see
Hypertension: ZOMIG should not be used in patients with uncontrolled or severe hypertension. Patients with mild to moderate hypertension should be treated cautiously at the lowest effective dose.

Cimetidine and other 1A2 Inhibitors: Patients taking cimetidine and other 1A2 inhibitors should not exceed a dose of 5 mg ZOMIG in any 24 hour period (see DRUG INTERACTIONS).

Recommended Dose and Dosage Adjustment

ZOMIG CONVENTIONAL TABLETS

Adults: The minimal effective single adult dose of ZOMIG is 1 mg. The recommended single dose is 2.5 mg. The 1 mg dose can be approximated by manually breaking a 2.5 mg conventional tablet in half.

In controlled clinical trials, single doses of 1 mg, 2.5 mg or 5 mg ZOMIG conventional tablets were shown to be effective in the acute treatment of migraine headaches. In the only direct comparison of the 2.5 and 5 mg doses, there was little added benefit from the higher dose, while side effects increased with 5 mg ZOMIG tablets (see ADVERSE EVENTS, Table 1, and Part II: CLINICAL TRIALS, Table 4).

ZOMIG RAPIMELT

Adults: The minimal effective single adult dose of ZOMIG is 1 mg. The recommended single dose is 2.5 mg. The ZOMIG RAPIMELT 2.5 mg orally disperisible tablet cannot be broken in half to approximate a 1 mg dose.

The ZOMIG RAPIMELT orally dispersible tablet rapidly dissolves when placed on the tongue and is swallowed with the patient’s saliva. ZOMIG RAPIMELT can be taken when water is not available thus allowing early administration of treatment for a migraine attack. This formulation may also be beneficial for patients who suffer from nausea and are unable to drink during a migraine attack, or for patients who do not like swallowing conventional tablets.

ZOMIG NASAL SPRAY

Adults: As stated for ZOMIG conventional tablets and ZOMIG RAPIMELT, the recommended initial starting dose of ZOMIG is 2.5 mg. For patients for whom a 2.5 mg dose of zolmitriptan is not optimally effective, a 5 mg dose of ZOMIG Nasal Spray is recommended.

In a controlled clinical trial, single doses of 0.5, 1.0, 2.5 and 5.0 mg ZOMIG Nasal Spray were shown to be effective in the acute treatment of migraine headaches (see Part II: CLINICAL TRIALS, Table 7). The 5 mg nasal spray dose provided significantly improved pain relief over 2.5 mg oral tablet (seen at 15, 30, 45, 60, and 120 minutes). The 2.5 mg dose of ZOMIG Nasal Spray did not provide any benefit over the 2.5 mg oral tablet.

ZOMIG Nasal Spray is administered as a single dose into one nostril. The nasal spray provides an alternative non-oral formulation of zolmitriptan to that of ZOMIG conventional tablets and ZOMIG RAPIMELT.
**Administration**

**ZOMIG CONVENTIONAL TABLETS**
The tablet should be swallowed with water.

**ZOMIG RAPIMELT**
The tablet should be placed on the tongue, where it will dissolve with the saliva. Water is not needed for the dispersible tablet.

**ZOMIG NASAL SPRAY**
The nasal spray should be administered into one nostril only. The device is a single dose unit and must not be primed before use. Patients should be advised to read the consumer information leaflet regarding the use of the nasal spray device prior to administration.

**OVERDOSAGE**
There is no experience with clinical overdose. Volunteers receiving single 50 mg oral doses of ZOMIG (zolmitriptan) commonly experienced sedation.

The elimination half-life of zolmitriptan is 2.5 - 3 hours (see ACTION AND CLINICAL PHARMACOLOGY), and therefore monitoring of patients after overdose with ZOMIG should continue for at least 15 hours or while symptoms or signs persist.

There is no specific antidote to zolmitriptan. In cases of severe intoxication, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system.

It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of zolmitriptan.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action and Pharmacodynamics**
ZOMIG (zolmitriptan) is a selective 5-hydroxytryptamine1 (5-HT_{1B/1D}) receptor agonist. It exhibits a high affinity at human recombinant 5-HT_{1B} and 5-HT_{1D} receptors and modest affinity for 5-HT_{1A} receptors. Zolmitriptan has no significant affinity (as measured by radioligand binding assays) or pharmacological activity at 5-HT_{2}, 5-HT_{3}, 5-HT_{4}, alpha_{1}, alpha_{2}, or beta_{1}, -adrenergic; H_{1}, H_{2}, histaminic; muscarinic; dopamine_{1}, or dopamine_{2}, receptors. The N-desmethyl metabolite of zolmitriptan (N-desmethylzolmitriptan) also has high affinity for 5-HT_{1B/1D} and modest affinity for 5-HT_{1A} receptors.

It has been proposed that symptoms associated with migraine headaches arise from the activation of the trigemino-vascular system, which results in local cranial vasodilation and neurogenic inflammation involving the antidromic release of sensory neuropeptides [Vasoactive Intestinal Peptide (VIP), Substance P and calcitonin gene related peptide (CGRP)]. The therapeutic activity of zolmitriptan for the treatment of migraine headache is thought to be attributable to its agonist effects at 5-HT_{1B/1D} receptors on the intracranial blood vessels, including the arteriovenous anastomoses, and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
**Pharmacokinetics**

**ZOMIG CONVENTIONAL TABLETS AND ZOMIG RAPIMELT**

**Absorption and Bioavailability:** In man, zolmitriptan is rapidly and well absorbed (at least 64%) after oral administration with peak plasma concentrations occurring in 2 hours. The mean absolute bioavailability of the parent compound is approximately 40%. Food has no significant effect on the bioavailability of zolmitriptan.

During a moderate to severe migraine attack in male and female patients, mean AUC\(_{0-4}\) and \(C_{\text{max}}\) for zolmitriptan were decreased by 40% and 25%, respectively and mean \(T_{\text{max}}\) was delayed by one-half hour compared to the same patients during a migraine free period.

Plasma Kinetics and Disposition: When given as a single dose to healthy volunteers, zolmitriptan displayed linear kinetics over the dose range of 2.5 to 50 mg.

**Distribution:** The mean apparent volume of distribution is 7.0 L/kg. Plasma protein binding of zolmitriptan over the concentration range of 10 - 1000 ng/L is 25%.

There is no evidence of accumulation on multiple dosing with zolmitriptan up to doses of 10 mg.

**Metabolism and Excretion:** Metabolism of zolmitriptan is dependent on CYP1A2 and the metabolism of the active metabolite N-desmethylzolmitriptan is via the monoamine oxidase A (MAOA) enzyme system. Zolmitriptan is eliminated largely by hepatic biotransformation followed by urinary excretion of the metabolites. The enzymes responsible for the metabolism of zolmitriptan remain to be fully characterized. The mean elimination half-life of zolmitriptan is approximately 2.5 to 3 hours. Mean total plasma clearance of zolmitriptan is 31.5 mL/min/kg, of which one-sixth is renal clearance. The renal clearance is greater than the glomerular filtration rate suggesting renal tubular secretion.

In a study in which radiolabelled zolmitriptan was orally administered to healthy volunteers, 64% and 30% of the administered \(^{14}\)C-zolmitriptan dose was excreted in the urine and feces, respectively. About 8% of the dose was recovered in the urine as unchanged zolmitriptan. The indole acetic acid and N-oxide metabolites, which are inactive, accounted for 31% and 7% of the dose, respectively, while the active metabolite N-desmethylzolmitriptan accounted for 4% of the dose.

Conversion of zolmitriptan to the active metabolite N-desmethylzolmitriptan occurs such that metabolite concentrations are approximately two thirds that of zolmitriptan. Because the 5-HT\(_{1B/1D}\) potency of N-desmethylzolmitriptan is 2 to 6 times that of the parent, the metabolite may contribute a substantial portion of the overall effect after zolmitriptan administration. The half-life of N-desmethylzolmitriptan is 3 hours and the \(T_{\text{max}}\) is approximately 2 to 3 hours.

**ZOMIG NASAL SPRAY**

**Absorption:** Zolmitriptan nasal spray is rapidly absorbed via the nasopharynx as detected in a Photon Emission Tomography (PET) study using \(^{11}\)C-zolmitriptan. Zolmitriptan was detected in plasma by 5 minutes and peak plasma concentration generally was achieved by 3 hours. (Approximately 40% of \(C_{\text{max}}\) is achieved between 10-15 minutes after dosing). The time at which maximum plasma concentrations were observed was similar after single (1 day) or multiple (4 day) nasal dosing. Plasma concentrations of zolmitriptan are sustained for 4 to 6
hours after dosing. Zolmitriptan displays linear kinetics after multiple doses of 2.5 mg, 5 mg, or 10 mg. Increases in zolmitriptan and N-desmethylzolmitriptan plasma concentrations were observed with multiple dosing but these were predictable from the single dose data and the dosing interval used in this study. The mean absolute bioavailability of ZOMIG Nasal Spray is approximately 41% and is similar to the tablet. The mean relative bioavailability of the nasal spray formulation is 102%, compared to the oral tablet.

Zolmitriptan and its active metabolite display dose proportionality after single or multiple dosing. Dose proportional increases in zolmitriptan and N-desmethylzolmitriptan $C_{\text{max}}$ and AUC were observed for 2.5 and 5 mg nasal spray doses. The pharmacokinetics for elimination of zolmitriptan and its active metabolite N-desmethylzolmitriptan are similar for all nasal spray dosages. N-desmethylzolmitriptan is detected in plasma by 15 minutes and peak plasma concentration is generally achieved by 3 hours after administration.

Food has no significant effect on the bioavailability of zolmitriptan.

**Distribution:** Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 - 1000 ng/mL. The mean ($\pm$SD) apparent volume of distribution for zolmitriptan nasal spray formulation is 8.3 ±3.6 L/kg.

**Metabolism and Excretion:** Metabolism of zolmitriptan is dependent on CYP1A2 and the metabolism of the active metabolite N-desmethylzolmitriptan is via the monoamine oxidase A (MAOA) enzyme system. The mean elimination half-life for zolmitriptan and N-desmethylzolmitriptan following nasal spray administration are approximately 3 hours, which is similar to the half-life values seen after oral tablet administration. The half-life values were similar for zolmitriptan and N-desmethylzolmitriptan after single (1 day) and multiple (4 day) nasal dosing.

Mean total plasma clearance is 25.9 mL/min/kg, of which one-sixth is renal clearance. The renal clearance is greater than the glomerular filtration rate suggesting renal tubular secretion.

The plasma concentrations and pharmacokinetics of zolmitriptan and the three major metabolites for the nasal spray and conventional tablet formulations are similar.

**Special Populations and Conditions**

**Adolescents (12 - 17 years of age):** In a single dose pharmacokinetic study of 5 mg zolmitriptan, systemic exposure to the parent compound was not found to differ significantly between adolescents and adults. However, plasma levels of the active metabolite were significantly greater (40 - 50%) in adolescents than adults.

**Geriatrics (>65 years of age):** Zolmitriptan pharmacokinetics in healthy elderly non-migraineur (non-migraine sufferers) volunteers (age 65 - 76) were similar to those in younger non-migraineur volunteers (age 18 - 39).

**Gender:** Mean plasma concentrations of zolmitriptan were up to 1.5-fold greater in females than in males.
**Race:** The effect of race on the pharmacokinetics of zolmitriptan has not been systematically evaluated. Retrospective analysis of pharmacokinetic data between Japanese and Caucasian subjects revealed no significant differences.

**Hepatic Insufficiency:** A study to evaluate the effect of liver disease on the pharmacokinetics of zolmitriptan showed that the AUC and $C_{\text{max}}$ were increased by 94% and 50% respectively in patients with moderate liver disease and by 226% and 47% in patients with severe liver disease compared with healthy volunteers. Exposure to the metabolites, including the active metabolite N-desmethylzolmitriptan, was decreased. For N-desmethylozolmitriptan, AUC and $C_{\text{max}}$ were reduced by 33% and 44% in patients with moderate liver disease and by 82% and 90% in patients with severe liver disease.

The effect of hepatic disease on the pharmacokinetics of zolmitriptan nasal spray has not been evaluated. Because of the similarity in exposure zolmitriptan tablets and nasal spray should have similar dosage adjustments and should be administered with caution in subjects with liver disease generally using doses less than 2.5 mg (see WARNINGS AND PRECAUTIONS).

The plasma half-life ($t_{1/2}$) of zolmitriptan was 4.7 hours in healthy volunteers, 7.3 hours in patients with moderate liver disease and 12 hours in those with severe liver disease. The corresponding $t_{1/2}$ values for N-desmethylozolmitriptan were 5.7 hours, 7.5 hours and 7.8 hours respectively.

Seven out of 27 patients with hepatic impairment (4 with moderate and 3 with severe liver disease) experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg dose. Zomitriptan should be administered with caution in subjects with moderate or severe liver disease (see WARNINGS AND PRECAUTIONS, Hepatic and DOSAGE AND ADMINISTRATION).

**Renal Insufficiency:** Following oral dosing in patients with severe renal impairment (ClCr $\geq 5 \leq 25$ mL/min), clearance of zolmitriptan was reduced by 25% compared to normal (ClCr $\geq 70$ mL/min). There was no significant change observed in the clearance of zolmitriptan in patients with moderate renal impairment (ClCr $\geq 26 \leq 50$ mL/min). The effects of renal impairment on the pharmacokinetics of zolmitriptan nasal spray have not been evaluated.

**Hypertension:** No differences in the pharmacokinetics of zolmitriptan were noted in mild to moderate hypertensive volunteers compared to normotensive controls. In this study involving a limited number of patients, small dose-dependent increases in systolic and diastolic blood pressure (approximately 3 mm Hg) did not differ between mild/moderate hypertensives and normotensive controls.

**STORAGE AND STABILITY**

ZOMIG conventional tablets, ZOMIG RAPIMELT and ZOMIG Nasal Spray should be stored at room temperature between 15 and 30ºC.
DOSAGE FORMS, COMPOSITION AND PACKAGING

Dosage Forms and Packaging

ZOMIG 2.5 mg conventional tablets are yellow, round biconvex film-coated tablets intagliated ‘Z’ on one side. Available in blister packs of 6 tablets.

ZOMIG RAPIMELT orally dispersible 2.5 mg tablets are white, round, uncoated tablets intagliated ‘Z’ on one side with a bevelled edge. Available in blister packs of 6 tablets.

ZOMIG Nasal Spray is packaged as a single dose spray unit and supplies either 2.5 mg or 5 mg of zolmitriptan. The blue coloured plastic device with a grey protection cap is packaged in a carton and labelled to indicate the nominal dose. Patients should be cautioned to not remove the grey protection cap until prior to dosing. The ZOMIG Nasal Spray device is placed in a nostril and actuated to deliver a single dose, after which the device must be discarded. Patients should be cautioned to avoid spraying the contents of the device in their eyes. ZOMIG Nasal Spray 2.5 mg strength is supplied in boxes of 2 single use nasal spray units. ZOMIG Nasal Spray 5 mg strength is supplied in boxes of 6 single use nasal spray units.

Composition

ZOMIG conventional tablets

Nonmedicinal ingredients: anhydrous lactose, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400 and 8000, sodium starch glycolate, titanium dioxide, yellow iron oxide.

ZOMIG RAPIMELT

Nonmedicinal ingredients: aspartame, citric acid, colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, orange flavour, sodium bicarbonate.

ZOMIG Nasal Spray

Nonmedicinal ingredients: citric acid, disodium phosphate (dodecahydrate or dihydrate), purified water.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: Zolmitriptan
Chemical Name: (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone

Molecular Formula and Molecular Mass: C_{16}H_{21}N_{3}O_{2} and 287.36

Structural Formula:

![Structural Formula]

Physiochemical Properties:

Solubility: slightly soluble in water (1.3 mg/mL at 25 °C), 0.1M hydrochloric acid (33 mg/mL at 25 °C)

pKa: 9.64 ± 0.01

Partition co-efficient: octanol-1-ol/water partition log KD=−1.0

Melting point: 136 °C
CLINICAL TRIALS

The efficacy of ZOMIG was not affected by the presence of aura and was independent of headache duration pre-treatment, relationship to menses, gender, age or weight of the patient, pre-treatment nausea and concomitant use of common migraine prophylactic drugs.

ZOMIG CONVENTIONAL TABLET

The efficacy of ZOMIG conventional tablets in the acute treatment of migraine attacks was evaluated in five randomized, double blind, placebo controlled studies, of which 2 utilized the 1 mg dose, 2 utilized the 2.5 mg dose and 4 utilized the 5 mg dose. In all studies, the effect of zolmitriptan was compared to placebo in the treatment of a single migraine attack. All studies used the marketed formulation. Study 1 was a single-centre study in which patients treated their headaches in a clinic setting. In the other studies, patients treated their headaches as outpatients. In Study 4, patients who had previously used sumatriptan were excluded, whereas in the other studies no such exclusion was applied. Patients enrolled in these five studies were predominantly female (82%) and Caucasian (97%) with a mean age of 40 years (range 12-65). Patients were instructed to treat a moderate to severe headache. Headache response, defined as a reduction in headache severity from moderate or severe pain to mild or no pain, was assessed at 1, 2, and, in most studies, 4 hours after dosing. Associated symptoms such as nausea, photophobia and phonophobia were also assessed. Maintenance of response was assessed for up to 24 hours post dose. A second dose of ZOMIG tablets or other medication was allowed 2 to 24 hours after the initial dose, to treat persistent and recurrent headache. The frequency and time to use of these additional treatments were also recorded.

Table 4 shows efficacy results for ZOMIG conventional tablets in 5 placebo-controlled trials, 4 of which were multi-centre. The percentage of patients with pain relief (grade1/0) at 2 hours after treatment (the primary endpoint measure) was significantly greater among patients receiving ZOMIG at all doses compared to those on placebo. In Study 3, which directly compared the 1 mg, 2.5 mg and 5 mg doses, there was a statistically significant greater proportion of patients with headache response at 2 hours in the higher dose groups (2.5 mg or 5 mg) than in the 1 mg group. There was no statistically significant difference between the 2.5 mg and 5 mg dose groups for the primary endpoint measure of pain relief (1/0) at 2 hours, or at any other time point measured.
## Table 4

**Percentage of Patients with Pain Relief (1/0)^* at 2 Hours - Intent to Treat Population**

<table>
<thead>
<tr>
<th>Study</th>
<th>Hour Post-dose</th>
<th>Placebo</th>
<th>ZOMIG Conventional Tablet Dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>15(\text{N=20})</td>
<td>27(\text{N=22})</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>21(\text{N=99})</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>32(\text{N=140})</td>
<td>50(^\dagger)(\text{N=141})</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
<td>44(\text{N=56})</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>36(\text{N=101})</td>
<td>-</td>
</tr>
</tbody>
</table>

*\(p \leq 0.05\) in comparison with placebo
**\(p \leq 0.01\) in comparison with 1 mg
\(^\dagger\)\(p \leq 0.01\) in comparison with placebo
- = Not studied

Pain Relief is defined as a reduction in headache severity from grade 3 or 2 (severe or moderate) to grade 1 or 0 (mild or no pain)

The proportion of patients being pain free at 2 hours was statistically significantly greater for patients receiving ZOMIG conventional tablets at doses of 1, 2.5 and 5 mg compared with placebo in Study 3.

For patients with migraine associated photophobia, phonophobia, and nausea at baseline, there was a decreased incidence of these symptoms following administration of ZOMIG as compared to placebo.

Two to 24 hours following the initial dose of study treatment, patients were allowed to use additional treatment for pain relief in the form of a second dose of study treatment or other medication. The probability of taking a second ZOMIG dose or other medication for migraine over 24 hours following the initial dose of study treatment was lower for ZOMIG treated groups as compared to placebo. For the 1 mg dose, the probability of taking a second dose was similar to placebo and greater than with either the 2.5 or 5 mg dose.

In an open label study conducted to evaluate long-term safety, patients treated multiple migraine headaches with 5 mg doses of zolmitriptan for up to 1 year. A total of 31,579 migraine attacks were treated during the course of the study (mean number of headaches treated per patient was 15). An analysis of patients who treated at least 30 migraine attacks of moderate or severe intensity (n = 233) suggests that the 2 hour headache response rate is maintained with repeated use of zolmitriptan.
ZOMIG RAPIMELT

The efficacy and tolerability of ZOMIG RAPIMELT 2.5 mg tablets in the acute treatment of adult patients with migraine was evaluated in an international, randomized, placebo-controlled, double-blind trial. A total of 471 patients [87% female; 97% Caucasian; mean age 41 years (18 - 62)] were exposed to trial medication, 231 were randomized to zolmitriptan and 240 to placebo. Each patient was instructed to treat a single migraine of moderate or severe intensity with double-blind medication. If sufficient relief was not obtained 2 hours after the first dose, a second dose or escape medication could be taken. Headache response, defined as a reduction of headache pain from moderate or severe at the time of treatment to mild or none at assessment, was evaluated at 0.5, 1, 2, and 4 hours after the first dose. The primary endpoint was headache response at 2 hours.

When compared to the placebo treatment group, a statistically significant greater proportion of the ZOMIG RAPIMELT group experienced a headache response within 2 hours of initial dosing (primary endpoint, see Table 5). Patients treating with ZOMIG RAPIMELT also had statistically significant headache response relative to placebo at 0.5, 1 and 4 hours post-dose.

Table 5 Percentage of Patients with Headache Response* at 2 Hours Post-Dose by Treatment Group (ITT Population)

<table>
<thead>
<tr>
<th></th>
<th>Placebo Treatment Group</th>
<th>Statistical Comparison of ZOMIG RAPIMELT versus Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZOMIG RAPIMELT Group</td>
<td>N = 236, Headache Response N (%)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>N = 236, Headache Response N (%)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>138 (63)</td>
<td>53 (22)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Percentages are based upon the total number of patients in the ITT population for which data were available at 2 hours following a single attack.

ITT Intent to treat population – the subset of randomized patients who received trial medication and who received at least one efficacy evaluation.

* Headache response is the diminution of headache pain from moderate or severe at the time of treatment to mild or none at the assessment.

Assessment of the number of patients who were pain-free after treating a migraine attack revealed that 27% of patients treating with ZOMIG RAPIMELT were pain free at 2 hours compared to 7% treating with placebo (p<0.001). The number of patients pain-free through 24 hours after treatment with a single dose of trial medication was also greater in the ZOMIG RAPIMELT (23%) than in the placebo (7%) group.

The median time to second treatment (second dose or escape medication) was more than twice as long in the ZOMIG RAPIMELT treatment group relative to placebo, 5 hours and 45 minutes versus 2 hours and 10 minutes.

The efficacy and tolerability of ZOMIG RAPIMELT 2.5 mg tablets in the acute treatment of adult patients with migraine was also evaluated in a second randomized, multi-centre, parallel-group, placebo-controlled, double-blind trial. A total of 565 patients [85% female; 85% Caucasian; mean age 41 years (18 - 65)] were randomized to zolmitriptan (n=281) or placebo (n=284) and consumed at least 1 dose of study medication. Each patient was instructed to treat two separate migraine headaches of mild, moderate, or severe intensity with double-blind medication. For each migraine, if sufficient relief was not obtained 2 hours after the first dose, a
second dose or escape medication could be taken. The primary endpoint was the overall pain-free response rate over two migraine attacks at 2 hours after dosing. Pain-free response was defined as an improvement in headache pain from mild, moderate or severe to no pain at assessment (2 hours after dosing). When compared to the placebo treatment group, a statistically significant proportion of the ZOMIG RAPIMELT group experienced a pain-free response within 2 hours of dosing (see Table 6).

Table 6  Pain Free Response* at 2 Hours Post-Dose by Treatment Group (ITT Population)

<table>
<thead>
<tr>
<th>Migraine Attack</th>
<th>ZOMIG RAPIMELT Group</th>
<th>Placebo Treatment Group</th>
<th>Statistical Comparison of ZOMIG RAPIMELT versus Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Pain-free Response N (%)a</td>
<td>N</td>
</tr>
<tr>
<td>Totalb</td>
<td>526</td>
<td>211 (40)</td>
<td>524</td>
</tr>
<tr>
<td>1st attackc</td>
<td>278</td>
<td>114 (41)</td>
<td>282</td>
</tr>
<tr>
<td>2nd attackc</td>
<td>248</td>
<td>97 (39)</td>
<td>242</td>
</tr>
</tbody>
</table>

a Percentages are based upon the total number of attacks (N) in the ITT population for which data were available at 2 hours.
b Primary efficacy endpoint was the overall pain-free response rate over 2 migraine attacks.
c The analysis of the first and second attacks individually was performed as a secondary variable and not statistically analysed.

ITT Intent to treat population – the subset of randomized patients who received trial medication and who received at least one efficacy evaluation.
* Pain-free response is the improvement in migraine headache pain intensity from mild, moderate or severe to no pain at the assessment.

Remedication rates were higher in the placebo group for both attacks, compared to the ZOMIG RAPIMELT treatment group and time to remedication was statistically significantly shorter in the placebo group (p<0.001).

Patients treating migraines with ZOMIG RAPIMELT were more likely to experience relief of nausea, photophobia, and phonophobia relative to placebo at the primary endpoint of 2 hours.

**ZOMIG Nasal Spray**

The efficacy of ZOMIG Nasal Spray in a dose-ranging study up to 5 mg in the acute treatment of migraine headache with or without aura was demonstrated in a randomized, outpatient, double-blind, multiple attack, placebo-controlled trial.

Patients were instructed to treat a moderate to severe headache. Headache response, defined as a reduction in headache severity from moderate or severe pain to mild or no pain, was assessed 15, 30, 45 minutes and 1, 2, and 4 hours after dosing. Pain free response rates were also assessed. A dose of escape medication was allowed 4 to 24 hours after the initial treatment for persistent and recurrent headache.

Of the 1372 patients treated in the study, 83% were female and 99% were Caucasian, with a mean age of 40.6 years (range 18 to 65 years).

The two hour headache response rates in patients treated with ZOMIG Nasal Spray were statistically significant among patients at all doses compared to placebo. There was a greater
percentage of patients with a headache response at 2 hours in the higher dose groups (See Table 7).

**Table 7** Percentage of Patients with Headache Response at 2 hours.

<table>
<thead>
<tr>
<th>Hour Post Dose</th>
<th>Placebo</th>
<th>ZOMIG Oral Tablet</th>
<th>ZOMIG Nasal Spray</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>2.5</td>
<td>0.5</td>
</tr>
<tr>
<td>2</td>
<td>30.6</td>
<td>61.3</td>
<td>41.5*</td>
</tr>
<tr>
<td>(N=389)</td>
<td>(N=400)</td>
<td>(N=398)</td>
<td>(N=427)</td>
</tr>
</tbody>
</table>

* p < 0.001 vs placebo  
** p < 0.05 vs oral zolmitriptan

At 15 minutes a significantly higher proportion of attacks were pain free following zolmitriptan nasal spray 5.0 and 2.5 mg compared with placebo. Also at 15 minutes a significantly greater proportion of patients were pain free with 5 mg nasal spray compared to 2.5 mg oral tablet.

**Comparative Bioavailability Studies**

ZOMIG RAPIMELT was found to be bioequivalent with the conventional tablet in terms of AUC and C_{max} for zolmitriptan and its active metabolite (N-desmethylzolmitriptan). The time to maximum plasma concentration following administration of ZOMIG RAPIMELT is similar for the active metabolite (N-desmethylzolmitriptan) but can be prolonged for zolmitriptan with this formulation relative to the conventional tablet. In a clinical pharmacology study to compare the two formulations, for the active metabolite N-desmethylzolmitriptan, the t_{max} ranged from 0.75 to 5 hours (median 3.0 hours) for the conventional tablet, and 1 to 6 hours (median 3.0 hours) for the orally dispersible tablet, whereas for zolmitriptan the ranges were 0.5 to 3 hours (median 1.5 hours) and 0.6 to 5 hours (median 3.0 hours), respectively. However, plasma concentrations of zolmitriptan for the orally dispersible and conventional tablet formulations are similar up to 45 minutes post dose.

**DETAILED PHARMACOLOGY**

**Pharmacodynamics**

**in vitro:** Receptor specificity studies using radioligand binding assays and isolated intact tissue assays have shown that zolmitriptan is a selective 5-HT_1 partial receptor agonist which exhibits a high affinity at human recombinant 5-HT_1D (pKi = 9.2) and 5-HT_1B (pKi = 8.2) receptors and modest affinity for 5-HT_1A receptors (pKi = 7.0). Zolmitriptan had no significant affinity or pharmacological activity at 5-HT_2, 5-HT_3, 5-HT_4, alpha_1, alpha_2, or beta_1, -adrenergic; H_1, H_2, histaminic; muscarinic; dopamine_1, or dopamine_2, receptors.

**in vivo:** In anesthetized animals, zolmitriptan (0.3 - 100 µg/kg i.v.) caused dose-related and sustained reductions in carotid arterial blood flow and conductance (ED_{50} for dogs: 2.9 µg/kg; for cats: 1.1 µg/kg). This reflected a constriction of cranial arteriovenous anastomoses (AVA), with a very minor contribution from the extracranial circulation. No equivalent reductions occurred in cerebral blood flow and conductance in these animals. At doses of 30 µg/kg and 100 µg/kg, i.v., zolmitriptan inhibited trigeminal ganglion electrically stimulated release of calcitonin.
gene related peptide in anesthetized cats. The effect of trigeminal ganglion stimulation on vasoactive intestinal peptide was also attenuated, in this animal model, by 100 µg/kg zolmitriptan administered i.v. Over a dose range of 3 - 30 µg/kg (i.v.), zolmitriptan caused a dose-related inhibition of neurogenic plasma protein extravasation into the ipsilateral dura mater following electrical stimulation of the trigeminal ganglion.

At higher doses (>100 µg/kg), zolmitriptan produced some systemic cardiovascular effects (notably inconsistent and poorly dose-related increases in blood pressure and heart rate in conscious animals). These systemic effects were species-specific and modified by anesthesia. Apart from its selective vasoconstrictor action in vascular beds supplied by the carotid artery, zolmitriptan had little or no effect at doses up to 1 mg/kg in other major systemic vascular beds, including the coronary and pulmonary circulations. Only in dog renal vasculature was zolmitriptan found also to cause dose-related vasoconstrictor responses.

Zolmitriptan elicited some central nervous system and behavioural effects at high doses (1 or 2 mg/kg), but the severity of these effects were species-specific.

Zolmitriptan exhibited no general autonomic effects, but at low doses (3 -100 µg/kg i.v.) had a selective effect on the sympathetic innervation to the carotid vasculature consistent with agonist activity at pre-junctional inhibitory 5-HT<sub>1D</sub>-like receptors.

Zolmitriptan did not cause any important respiratory effects except at high doses (>1 mg/kg). However, at these doses other central nervous system and behavioural effects may contribute.

Zolmitriptan had no effects on gastrointestinal function except at very high doses (30 mg/kg, p.o.). Likewise, the drug was without important effect on renal function and barbiturate sleeping times.

The metabolism of zolmitriptan in man results in the formation of a pharmacologically active N-demethylated derivative (see Part I: ACTION AND CLINICAL PHARMACOLOGY). This metabolite exhibited the same pharmacological specificity as the parent molecule, but was 2 to 6 times more potent at 5-HT<sub>1D</sub> receptors. The cardiovascular profile of the metabolite was qualitatively the same as that of zolmitriptan.

Pharmacokinetics

Absorption of radiolabelled drug-related material was rapid following oral administration of zolmitriptan to mice, rats, rabbits and dogs with C<sub>max</sub> occurring within 1 hour of dosing. In the rat, C<sub>max</sub> was reached at 0.5 hour with a secondary peak at 3 hours after dosing. This occurred in both males and females. A second peak was not detected following intravenous administration therefore it is likely a result of continuing absorption lower in the gastrointestinal tract. Oral bioavailabilities of 50% in mice (10 mg/kg), 41% in rats (10 mg/kg), 25% in rabbits (10 mg/kg) and 79% in dogs (2 mg/kg) suggest significant first pass metabolism, particularly in the rabbit. In man, absorption is at least 64% after oral administration, with a mean absolute bioavailability of the parent compound of approximately 40%.

Preclinical studies in the rat, rabbit, and Cynomolgus monkey have shown that the disposition of zolmitriptan is similar following nasal and oral administration. Total recoveries of radioactivity in urine and feces following oral administration of zolmitriptan were 65% and 30% of the administered dose, respectively. About 8% of the oral dose was recovered in the urine as
unchanged zolmitriptan. The indole acetic acid metabolite accounted for 31% of the dose, followed by N-oxide (7%) and N-desmethylzolmitriptan (4%). The indole acetic acid and N-oxide metabolites are inactive. In addition, preclinical studies in the rat and rabbit have shown that the disposition of zolmitriptan is similar following single and multiple nasal and oral administration.

In all animal species elimination from plasma was rapid with $t_{\frac{1}{2}}$ of 1 to 2 hours. There were no apparent differences due to gender or route of administration. The $t_{\frac{1}{2}}$ in man was 2.5 to 3 hours.

In the toxicity studies, exposure was generally linear with increasing dose. The pharmacokinetics following multiple dosing were similar to those observed after single dose administration. However, in the rat, exposures to zolmitriptan and the indole acetic acid metabolite increased time-dependently for the first 52 weeks of chronic dosing and subsequently decreased at 78 and 104 weeks. In the teratology studies, the exposure to zolmitriptan and the metabolites were not significantly different between pregnant and non-pregnant rats. However, in female rabbits, there appeared to be an increase in exposure over the dosing period. After chronic dosing to the dog, there was a slight variation in exposure to the N-oxide metabolite that increased relative to zolmitriptan.

The tissue distribution of zolmitriptan was investigated in the male rat using both albino and pigmented strains. The highest levels of distribution were found in the liver, kidney and glandular tissues. Minimal crossing of the blood-brain barrier was observed. The radioactive drug-related material was rapidly eliminated. Levels of radioactivity in the tissue of albino and pigmented rats were comparable at all time points, apart from the eye which had higher levels in the pigmented rat, indicating an association with melanin. In a study with pigmented rats, in which animals were given a single oral dose of 10 mg/kg radiolabelled zolmitriptan, radioactivity was notable in the eye up to 7 days (last time point examined) after drug administration and was still 75% of the value measured at the 4 hour time point post-dose.

Studies in pregnant rats and rabbits demonstrated exposure to the placenta and fetus while nursing rats had milk levels of radioactivity equivalent to plasma at 1 hour post dose and four times higher than plasma at 4 hours post dose.

Metabolite patterns of zolmitriptan are qualitatively similar in all animal species and man. Zolmitriptan was the major component of all urinary and faecal samples from mice, rats and rabbits while the indole acetic acid metabolite formed the major component in dogs and man.

Drug-related material was rapidly excreted in all species. Urine was the primary route of excretion, >50% of the dose, except after oral dosing to rodents that accounted for 30-35% of the dose. Biliary excretion in the rat was minimal (<4%) despite the excretion of 22% of an intravenous dose, indicating direct secretion into the gut.

**TOXICOLOGY**

**Acute Toxicity**

In oral acute studies in mice the approximate lethal dose of zolmitriptan was 1000 mg/kg and in rats the approximate lethal dose was between 1000 and 1500 mg/kg. Although exposure was not measured, the approximate oral lethal dose of zolmitriptan in rodents is about 20,000 times the
usual human dose of 2.5 mg. The approximate lethal dose was 50 - 100 mg/kg following intravenous administration. Animals were found dead without premonitory signs.

**Long-Term Toxicity**

Repeated dose studies in rats (up to 1000 mg/kg/day) and dogs (up to 100 mg/kg/day) have revealed little toxicity other than clinical signs, which are associated with an excess of the pharmacological action of this class of compound. Dose limiting factors were: in rats, sporadic deaths at the highest dose level, in dogs, clinical and behavioural changes, believed to be due to perturbations of 5-HT1D regulated central nervous system pathways. Details of each study are provided in Table 8.

In toxicity studies in which zolmitriptan nasal spray formulation was administered to rats (6 times daily for up to 6 months) and monkeys (8 times daily for 1 month) by the nasal route, the formulation was generally well tolerated. In monkeys, there was no indication of systemic toxicity or local irritation in the nasal cavity. In rats, a reversible minimal or mild rhinitis and nasopharyngitis was observed after 1 month at 72 mg/kg/day, with a no effect level of 18 mg/kg/day. This corresponds to approximately four-fold the maximum daily human exposure when expressed in terms of exposure per unit area of the nasal epithelium. There was no similar finding after 6 months of intranasal dosing at 72 mg/kg/day. Zolmitriptan nasal spray formulation is practically a non-irritant to the rabbit eye.
<table>
<thead>
<tr>
<th>TYPE</th>
<th>STUDY</th>
<th>SPECIES</th>
<th>NO/GROUP</th>
<th>DOSE</th>
<th>FINDINGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral/Intravenous Administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One Month Toxicity</td>
<td>Daily dosing oral</td>
<td>Wistar rat</td>
<td>15/15</td>
<td>0, 100, 400, 1600/1000 from day 10</td>
<td>Excessive mortality at 1600 mg. Very slight urothelial hyperplasia in a few 1600/1000 mg animals. Pink extremities all dose levels. 3 deaths at 400 mg. Slight increase in thyroid weight at 1600/1000 mg. No toxic effect level 100 mg/kg/day.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Beagle dog</td>
<td>3/3 Groups 2+3 5/5 Groups 1+4</td>
<td>0, 5, 25, 100</td>
<td>Clinical signs at all dose levels which reduced with continued dosing. One 100 mg animal collapsed on two occasions but survived. Withdrawal signs: mydriasis, photophobia. No toxic effect level 25 mg/kg/day.</td>
</tr>
<tr>
<td>One Month Toxicity</td>
<td>Daily dosing intravenous</td>
<td>Wistar rat</td>
<td>15/15</td>
<td>0, 0.5, 2, 10</td>
<td>Expected clinical signs at 2 and 10 mg. No irritation at injection site. No toxic effect level 10 mg/kg/day.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Beagle dog</td>
<td>3/3 Groups 2 + 3 5/5 Groups 1 + 4</td>
<td>0, 1, 5, 20</td>
<td>Clinical signs at all dose levels. No irritation at injection site. No toxic effect level 20 mg/kg/day.</td>
</tr>
<tr>
<td>Six Month Toxicity</td>
<td>Daily dosing oral</td>
<td>Wistar rat</td>
<td>30/30</td>
<td>0, 25, 100, 400</td>
<td>Flushed extremities at all dose levels. Low incidence of minimal thyroid hypertrophy at 400 mg/day. Slight increase in liver weight at 400 mg/kg/day. Sporadic deaths at 400 mg/kg/day. No toxic effect level 100 mg/kg/day.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Beagle dog</td>
<td>3/3 Groups 2 + 3 5/5 Groups 1 + 4</td>
<td>0, 5, 25, 100</td>
<td>Clinical signs at all dose levels which reduced on continued dosing. One dog treated with 25 mg/kg was killed due to severe clinical signs. No toxic effect level 100 mg/kg/day.</td>
</tr>
<tr>
<td>Twelve Month Toxicity</td>
<td>Daily dosing oral</td>
<td>Beagle dog</td>
<td>4/4 Groups 2 + 3 6/6 Groups 1 + 4</td>
<td>0, 5, 25, 100</td>
<td>Clinical signs at all dose levels. One 5 mg male and one 25 mg sacrificed because of aggression. One 100 mg male died on day 280. No toxic effect level 25 mg/kg/day.</td>
</tr>
<tr>
<td>TYPE</td>
<td>STUDY</td>
<td>SPECIES</td>
<td>No/GROUP M/F</td>
<td>DOSE mg/kg/day</td>
<td>FINDINGS</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------------------</td>
<td>---------</td>
<td>--------------</td>
<td>----------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Nasal Administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One month Toxicity</td>
<td>Daily dosing Intranasally</td>
<td>Rat</td>
<td>40/40</td>
<td>0, 18, 36, 72</td>
<td>Clinical signs at all dose levels. Minor Rhinitis in high dose males and females, and mid-dose males. Nasopharyngitis in high dose males and females. No signs of systemic toxicity, NOEL 18 mg/kg/day.</td>
</tr>
<tr>
<td>One month Toxicity</td>
<td>Daily dosing Intranasally</td>
<td>Rat</td>
<td>Group 1: 20/20 Group 2, 3: 10/10</td>
<td>0, 72</td>
<td>Treatment well tolerated. Rhinitis and Nasopharyngitis of minimal to mild severity was observed, with histopathological effects being reversible.</td>
</tr>
<tr>
<td>Six month Toxicity</td>
<td>Daily dosing Intranasally</td>
<td>Rat</td>
<td>Groups 1, 5: 30/30 Groups 2, 3, 4: 20/20</td>
<td>0, 6, 18, 72</td>
<td>Treatment was well tolerated and there were no histopathological findings attributable to either the dosing regime or the nasal spray.</td>
</tr>
<tr>
<td>One month Toxicity</td>
<td>3 Times Daily Dosing Intranasally</td>
<td>Monkey</td>
<td>Group 1, 4: 6/6 Group 2, 3: 3/3</td>
<td>0, 15, 30</td>
<td>No associated changes suggestive of local irritancy or overt systemic toxicity</td>
</tr>
<tr>
<td>One month Toxicity</td>
<td>Up to 8 times a day Intranasally</td>
<td>Monkey</td>
<td>Groups 1, 2, 3: 3/3</td>
<td>0, 16, 32, 64</td>
<td>Systemic exposure was demonstrated at all dose levels and no signs of systemic toxicity or local irritation were observed</td>
</tr>
</tbody>
</table>
REFERENCES


IMPORTANT: PLEASE READ

PART III: CONSUMER INFORMATION

ZOMIG® and ZOMIG RAPIMELT®
zolmitriptan

This leaflet is part III of a three-part “Product Monograph” published when ZOMIG and ZOMIG RAPIMELT were approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about ZOMIG and ZOMIG RAPIMELT. Contact your doctor or pharmacist if you have any questions about the drug.

REMEMBER: this medicine was prescribed only for YOU. Only a doctor knows who can use it safely. Never give it to someone else. It may harm them, even if their symptoms are the same as yours.

ABOUT THIS MEDICATION

The name of your medicine is ZOMIG or ZOMIG RAPIMELT which can only be obtained by prescription from your doctor. The decision to use ZOMIG/ZOMIG RAPIMELT is one that you and your doctor should make jointly, taking into account your individual preferences and medical circumstances. If you have risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease, or you are a post-menopausal female, or a male over 40), tell your doctor. Your doctor should evaluate you for heart disease in order to determine if ZOMIG/ZOMIG RAPIMELT are appropriate for you.

WHAT THE MEDICATION IS USED FOR:
ZOMIG and ZOMIG RAPIMELT belong to a group of antimigraine drugs called 5-HT1 agonists. ZOMIG/ZOMIG RAPIMELT is used to relieve your migraine headache and other associated symptoms of a migraine attack.

ZOMIG/ZOMIG RAPIMELT should not be used continuously to prevent or reduce the number of attacks you experience. Use ZOMIG/ZOMIG RAPIMELT only to treat an actual migraine headache attack.

WHAT IT DOES:
Migraine headache is believed to be caused by a widening of the blood vessels in the head. ZOMIG/ZOMIG RAPIMELT narrows the vessels and relieves the pain and other symptoms of migraine headache.

WHEN IT SHOULD NOT BE USED:
ZOMIG/ZOMIG RAPIMELT should not be used if:

- you are allergic to zolmitriptan or any of the other ingredients in ZOMIG/ZOMIG RAPIMELT (see “WHAT THE NONMEDICINAL INGREDIENTS ARE”)
- you have a history, or any symptoms or signs of a heart condition
- you suffer from chest pain, occurring either on exertion or at rest (the latter condition is known as Prinzmetal’s Angina)
- you have severe or uncontrolled hypertension
- you are taking or have recently taken (within 24 hours) an ergotamine containing or ergot-like drug, or another triptan used to treat migraines
- you have another type of headache that is different from a migraine attack
- you are taking or have recently taken (within 2 weeks) a monoamine oxidase inhibitor (MAOI)

WHAT THE MEDICINAL INGREDIENT IS:
Both ZOMIG and ZOMIG RAPIMELT tablets contain 2.5 mg of zolmitriptan as the active ingredient.

WHAT THE IMPORTANT NONMEDICINAL INGREDIENTS ARE:
ZOMIG contains: anhydrous lactose, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, and yellow iron oxide.

ZO MIG RAPIMELT contains: aspartame, citric acid, colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, orange flavour, and sodium bicarbonate. Each 2.5 mg ZOMIG RAPIMELT contains 2.81 mg of phenylalanine.

WHAT DOES IT COMES IN:
ZOMIG is supplied in conventional tablets of 2.5 mg in blister packs containing 6 tablets. ZOMIG RAPIMELT is supplied in orally dispersible tablets of 2.5 mg in blister packs containing 6 tablets.

WARNINGS AND PRECAUTIONS

BEFORE you use ZOMIG/ZOMIG RAPIMELT talk to your doctor or pharmacist if the answer to any of the following questions is YES, or if you do not know the answer:

- Are you pregnant, think you might be pregnant, or trying to become pregnant? Are you using inadequate contraception? Are you breastfeeding?

- Do you or have you ever experienced any pain or tightness in the chest, (which may or may not spread to your neck, jaw, or upper arm), shortness of breath, or irregular heart beats (including a fast heart beat called Wolff-Parkinson-White syndrome)? Do you have angina? Have you ever had heart or blood vessel disease? Do you have a history of cerebral bleeding? Have you had a heart attack or stroke?
• Do you have risk factors for heart disease, such as: high blood pressure, high cholesterol, smoking, obesity, diabetes, or strong family history of heart disease?
• Do you have a condition called phenylketonuria (a specific blood disorder)?
• Do you have rare hereditary problems of galactose intolerance?
• Are you post-menopausal or a male over 40?
• Do you have high blood pressure?
• Have you ever had to stop taking this or any other medication because of an allergy or other problems?
• Are you taking any other migraine 5-HT\textsubscript{1} agonist medications such as sumatriptan succinate, naratriptan hydrochloride, rizatriptan benzoate, almotriptan malate or migraine medications containing ergotamine, dihydroergotamine, or methysergide?
• Are you taking any medications for depression such as selective serotonin reuptake inhibitors (SSRI’s), for example, fluoxetine hydrochloride, sertraline hydrochloride, fluvoxamine maleate, paroxetine hydrochloride, etc., or serotonin norepinephrine reuptake inhibitors (SNRIs), for example, venlafaxine hydrochloride, or monoamine oxidase inhibitors (MAOIs), for example, phenelzine sulfate, tryptophan, or moclobemide?
• Have you ever experienced numbness on one side of your body when you have a headache?
• Have you ever had epilepsy or seizures?
• Have you ever had liver disease?
• Are you over 65 years of age?
• Is this headache different from your usual migraine attacks?
• Are you taking cimetidine (for treatment of indigestion or stomach ulcers) or a member of the quinolone family of antibiotics (for example ciprofloxacin)?

As with other migraine treatments, using too much ZOMIG/ZOMIG RAPIMELT can cause daily headaches or can make your migraine headaches worse. Ask your doctor if you think that this is the case for you. You may need to stop using ZOMIG/ZOMIG RAPIMELT to correct the problem.

ZOMIG tablets contain lactose which is a type of sugar. If you have been told by your doctor that you cannot tolerate or digest milk or some sugars, talk to your doctor before taking this medicine.

**Use of ZOMIG/ZOMIG RAPIMELT during pregnancy:**
Do not use ZOMIG or ZOMIG RAPIMELT if you are pregnant, think you might be pregnant, are trying to become pregnant or are using inadequate contraception, unless you have discussed this with your doctor.

**INTERACTIONS WITH THIS MEDICATION**

Tell your doctor or pharmacist about any other drugs, vitamins, minerals, natural supplements or alternative medicines you take, including:

- other 5-HT\textsubscript{1} agonist migraine drugs (sumatriptan succinate, naratriptan hydrochloride, rizatriptan benzoate, almotriptan malate) or migraine drugs that contain ergotamine, dihydroergotamine, methysergide
- drugs for depression such as selective serotonin reuptake inhibitors (SSRI’s), for example, fluoxetine hydrochloride, sertraline hydrochloride, fluvoxamine maleate, paroxetine hydrochloride, etc., or serotonin norepinephrine reuptake inhibitors (SNRIs), for example, venlafaxine hydrochloride, or monoamine oxidase inhibitors (MAOIs), for example, phenelzine sulfate, tryptophan, or moclobemide
- drugs used to treat upset stomach or stomach ulcers (cimetidine)
- antibiotics from the quinolone family (for example ciprofloxacin)
- Herbal remedies containing St John’s wort

Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those that can be bought without a prescription.

**PROPER USE OF THIS MEDICATION**

**USUAL DOSE:**

**Adults**
The usual dosage is 2.5 mg, or lower if recommended by your doctor. A lower dose can be obtained by manually breaking a conventional tablet in half. The ZOMIG RAPIMELT 2.5 mg orally dispersible tablets cannot be broken in half. The dose should be taken as soon as your migraine appears, but it may be taken at any time during your migraine headache. Swallow your dose with water.

For ZOMIG RAPIMELT orally dispersible tablets, the blister pack should be peeled open as shown on the foil (tablets should not be pushed through the foil). The ZOMIG RAPIMELT tablet should be placed on the tongue, where it will dissolve with the saliva. Water is not needed for the dispersible tablet.

A second dose may be taken if your headache returns, but not sooner than 2 hours following the first tablet. For any attack where you have no response to the first dose, do not take a second dose without first consulting your doctor.

Do not administer more than 10 mg in any 24 hour period.

**OVERDOSE:**
If you have taken more medication than your doctor has instructed, contact either your doctor, hospital emergency department, or nearest poison control centre immediately.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

Although the vast majority of ZOMIG and ZOMIG RAPIMELT users have not experienced any significant problems, you should be aware that the following side effects may occur.

Commonly reported side effects of ZOMIG and ZOMIG RAPIMELT are:
- feeling sick
- vomiting
- dizziness
- tiredness
- weakness

ZOMIG may commonly cause drowsiness. Do not drive or operate machinery until you are sure that you are not drowsy.

Other common side effects include:
- muscle aches and pains
- difficulty swallowing
- dry mouth
- headache
- stomach pain

Uncommon side effects include:
- increase in the production of urine or in the frequency of urination

Tell your doctor of these symptoms at your next visit.

Migraineurs may be at risk of certain cerebrovascular events such as cerebral bleeding and stroke. In very rare cases, as with other drugs of this type, such diseases have been reported in association with the use of zolmitriptan.

In very rare cases, as with other drugs of this type (5HT1 agonists), the following side effects have been reported:
- spasm of the blood vessels of the heart
- spasm of the blood vessels of the Gastro-Intestinal tract and spleen with possible infarctions

See the following table for what to do about serious side effects.

### SERIOUS SIDE EFFECTS OF ZOMIG AND ZOMIG RAPIMELT, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common (frequency greater than or equal to 1% but in less than 10% of patients)</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td>Irregular heart beat</td>
<td></td>
<td>✅</td>
</tr>
<tr>
<td>Sensations of pain, pressure or tightness in the chest, neck, throat, jaw, arms, or legs</td>
<td></td>
<td>✅</td>
</tr>
<tr>
<td>Sensations of tingling, heat, heaviness or pressure</td>
<td></td>
<td>✅</td>
</tr>
<tr>
<td>Uncommon (frequency greater than or equal to 0.1% but in less than 1% of patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fast heart rate</td>
<td></td>
<td>✅</td>
</tr>
<tr>
<td>Temporary increase in blood pressure</td>
<td></td>
<td>✅</td>
</tr>
<tr>
<td>Rare (frequency greater than or equal to 0.01% but in less than 0.1% of patients)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For any unexpected effects while taking ZOMIG/ZOMIG RAPIMELT, contact your doctor or pharmacist.

**HOW TO STORE IT**

Keep your medicine in a safe place where children cannot reach it. ZOMIG and ZOMIG RAPIMELT could be harmful to children. Store your medication between 15 and 30°C, away from direct heat.

If your doctor decides to stop your treatment, return your medication to the pharmacist for disposal. Do not take your medication after the expiry date on the package and blister foil. Return the tablets to your pharmacist for disposal.

**REPORTING SIDE EFFECTS**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (http://www.hc-sc.gc.ca/dhp-mbps/medeff/report-declaration/index-eng.php) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*
NOTE: This INFORMATION FOR THE CONSUMER leaflet provides you with the most current information at the time of printing.

For the most current information, the Consumer Information Leaflet plus the full Product Monograph, prepared for health professionals can be found at: www.astrazeneca.ca or by contacting the sponsor, AstraZeneca Canada Inc. at:
Customer Inquiries – 1 (800) 668-6000,

This leaflet was prepared by AstraZeneca Canada Inc., Mississauga, Ontario, L4Y 1M4

ZOMIG® and ZOMIG RAPIMELT® are registered trademarks of IPR Pharmaceuticals, Inc., used under license by AstraZeneca Canada Inc.

The AstraZeneca logo is a registered trademark of AstraZeneca AB, used under license by AstraZeneca Canada Inc.

©AstraZeneca 1998 - 2019

Last revised: December 11, 2019
IMPORTANT: PLEASE READ

PART III:
CONSUMER INFORMATION

ZOMIG® NASAL SPRAY
zolmitriptan

This leaflet is part III of a three-part "Product Monograph" published when ZOMIG NASAL SPRAY was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about ZOMIG NASAL SPRAY. Contact your doctor or pharmacist if you have any questions about the drug.

REMEMBER: this medicine was prescribed only for YOU. Only a doctor knows who can use it safely. Never give it to someone else. It may harm them, even if their symptoms are the same as yours.

ABOUT THIS MEDICATION

The name of your medicine is ZOMIG Nasal Spray which can only be obtained by prescription from your doctor. The decision to use ZOMIG Nasal Spray is one that you and your doctor should make jointly, taking into account your individual preferences and medical circumstances. If you have risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease, or you are a post-menopausal female, or a male over 40), tell your doctor. Your doctor should evaluate you for heart disease in order to determine if ZOMIG Nasal Spray is appropriate for you.

WHAT THE MEDICATION IS USED FOR:
ZOMIG Nasal Spray belongs to a group of anti-migraine drugs called 5-HT1 agonists. ZOMIG Nasal Spray is used to relieve your migraine headache and other associated symptoms of a migraine attack.

ZOMIG Nasal Spray should not be used continuously to prevent or reduce the number of attacks you experience. Use ZOMIG Nasal Spray only to treat an actual migraine headache attack.

WHAT IT DOES:
Migraine headache is believed to be caused by a widening of the blood vessels in the head. ZOMIG Nasal Spray narrows the vessels and relieves the pain and other symptoms of migraine headache.

WHEN IT SHOULD NOT BE USED:
ZOMIG Nasal Spray should not be used if:
• you have a history, or any symptoms or signs of a heart condition
• you suffer from chest pain, occurring either on exertion or at rest (the latter condition is known as Prinzmetal’s Angina)
• you have severe or uncontrolled hypertension
• you are taking or have recently taken (within 24 hours) an ergotamine containing or ergot-like drug, or another triptan used to treat migraines
• you have another type of headache that is different from a migraine attack
• you are taking or have recently taken (within 2 weeks) a monoamine oxidase inhibitor (MAOI)

WHAT THE MEDICINAL INGREDIENT IS:
Each ZOMIG Nasal Spray device contains either 2.5 mg or 5 mg of zolmitriptan in a unit dose.

WHAT THE IMPORTANT NONMEDICINAL INGREDIENTS ARE:
Each ZOMIG Nasal Spray device contains: citric acid, disodium phosphate (dodecahydrate or dihydrate), and water.

WHAT DOSAGE FORMS IT COMES IN:
ZOMIG Nasal Spray is supplied as a single dose spray unit in a blue coloured plastic device, with a grey protection cap. Each Nasal Spray delivers either 2.5 or 5 mg of drug.

WARNINGS AND PRECAUTIONS

BEFORE you use ZOMIG Nasal Spray talk to your doctor or pharmacist if the answer to any of the following questions is YES, or if you do not know the answer:
• Are you pregnant, think you might be pregnant, or trying to become pregnant? Are you using inadequate contraception? Are you breastfeeding?
• Do you or have you ever experienced any pain or tightness in the chest, (which may or may not spread to your neck, jaw, or upper arm), shortness of breath, or irregular heart beats (including a fast heart beat called Wolff-Parkinson-White syndrome)? Do you have angina? Have you ever had heart or blood vessel disease? Do you have a history of cerebral bleeding? Have you had a heart attack or stroke?
• Do you have risk factors for heart disease, such as: high blood pressure, high cholesterol, smoking, obesity, diabetes, or strong family history of heart disease?
• Are you post-menopausal or a male over 40?
• Do you have high blood pressure?
• Have you ever had to stop taking this or any other medication because of an allergy or other problems?
• Are you taking any other migraine 5-HT1 agonist medications such as sumatriptan succinate, naratriptan hydrochloride, rizatriptan benzoate, almotriptan malate or migraine medications containing ergotamine, dihydroergotamine, or methysergide?
• Are you taking any medications for depression such as selective serotonin reuptake inhibitors (SSRI’s), for example, fluoxetine hydrochloride, sertraline

COPYRIGHT 1998 - 2019 ASTRAZENECA CANADA INC.  Page 44 of 47
hydrochloride, fluvoxamine maleate, paroxetine hydrochloride, etc., or serotonin norepinephrine reuptake inhibitors (SNRIs), for example, venlafaxine hydrochloride, or monoamine oxidase inhibitors (MAOIs), for example, phenelzine sulfate, tranylcypromine sulfate or moclobemide?

- Have you ever experienced numbness on one side of your body when you have a headache?
- Have you ever had epilepsy or seizures?
- Have you ever had liver disease?
- Are you over 65 years of age?
- Is this headache different from your usual migraine attacks?
- Are you taking cimetidine (for treatment of indigestion or stomach ulcers) or a member of the quinolone family of antibiotics (for example ciprofloxacin)?

As with other migraine treatments, using too much ZOMIG Nasal Spray can cause daily headaches or can make your migraine headaches worse. Ask your doctor if you think that this is the case for you. You may need to stop using ZOMIG Nasal Spray to correct the problem.

**Use of ZOMIG Nasal Spray during pregnancy:**
Do not use ZOMIG Nasal Spray if you are pregnant, think you might be pregnant, are trying to become pregnant or are using inadequate contraception, unless you have discussed this with your doctor.

**INTERACTIONS WITH THIS MEDICATION**

Tell your doctor or pharmacist about any other drugs, vitamins, minerals, natural supplements or alternative medicines you take, including:

- other 5-HT1 agonist migraine drugs (sumatriptan succinate, naratriptan hydrochloride, rizatriptan benzoate, almotriptan maleate) or migraine drugs that contain ergotamine, dihydroergotamine, methysergide
- drugs for depression such as selective serotonin reuptake inhibitors (SSRIs), for example, fluoxetine hydrochloride, sertraline hydrochloride, fluvoxamine maleate, paroxetine hydrochloride, etc., or serotonin norepinephrine reuptake inhibitors (SNRIs), for example, venlafaxine hydrochloride, or monoamine oxidase inhibitors (MAOIs), for example, phenelzine sulfate, tranylcypromine sulfate or moclobemide
- drugs used to treat upset stomach or stomach ulcers (cimetidine)
- antibiotics from the quinolone family (for example ciprofloxacin)
- Herbal remedies containing St John’s wort

Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those that can be bought without a prescription.

**PROPER USE OF THIS MEDICATION**

**USUAL DOSE:**

**Adults**
The usual dose is a single nasal spray administration into one nostril. If your headache comes back after your initial dose, a second dose may be administered anytime after 2 hours of administering the first dose. For any attack where you have no response to the first dose, do not take a second dose without prior consultation with your doctor. Do not administer more than a total of 10 mg of ZOMIG in any 24-hour period.

The ZOMIG Nasal Spray unit consists of the following parts:

- **Protective Cover:** This covers the nozzle to protect it. It must be removed before you use the nasal spray device (Figure 1A).
- **Nozzle:** This is the part that you put into your nostril. The medicine comes out of a tiny hole in the top (Figure 1B).
- **Finger-grip:** This is the part that you hold when you use the spray.
- **Plunger:** This is the part that you press when you have inserted the nozzle comfortably into your nostril. This device works only once.

Steps for using ZOMIG Nasal Spray (Please read all steps prior to use):

1. Blow your nose gently before use. Remove the protective cover (Figure 1A). Hold the nasal spray gently with your fingers and thumb as shown in the picture (Figure 1B).

   **Do not press the plunger until you have put the nozzle into your nostril or you will lose the dose.**

2. Block one nostril by pressing firmly on the side of your nose (Figure 2). Either nostril can be used.

   **Do not press the plunger yet. Do not spray the contents of the device in your eyes.**

3. Put the nozzle (B) of the nasal spray device into the other nostril as far as feels comfortable (Figure 3). Tilt your head slightly as shown in the picture. Breathe in gently through...
your nose and at the same time press the plunger firmly with your thumb. The plunger may feel stiff and you may hear a click.

Figure 3
Keep your head slightly tilted back and remove the nozzle from your nose. Breathe gently through your mouth for 5-10 seconds. You may feel liquid in your nose. This is normal and will soon pass.

OVERDOSE:
If you have taken more medication than your doctor has instructed, contact either your doctor, hospital emergency department, or nearest poison control centre immediately.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Although the vast majority of ZOMIG Nasal Spray users have not experienced any significant problems, you should be aware of the following side effects:

A very commonly reported side effect of ZOMIG Nasal Spray is disturbed taste that is normal and will pass soon.

Commonly reported side effects of ZOMIG Nasal Spray are:
- feeling sick
- vomiting
- dizziness
- tiredness
- weakness

ZOMIG may commonly cause drowsiness. Do not drive or operate machinery until you are sure that you are not drowsy.

Other common side effects include:
- muscle aches and pains
- difficulty swallowing
- dry mouth
- headache
- stomach pain
- discomfort inside the nose
- nose-bleed

Uncommon side effects include:
- increase in the production of urine or in the frequency of urination

Tell your doctor of these symptoms at your next visit.

Migraineurs may be at risk of certain cerebrovascular events such as cerebral bleeding and stroke. In very rare cases, as with other drugs of this type, such diseases have been reported in association with the use of zolmitriptan.

In very rare cases, as with other drugs of this type (5HT₁ agonists), the following side effects have been reported:
- spasm of the blood vessels of the heart
- spasm of the blood vessels of the Gastro-Intestinal tract and spleen with possible infarctions

See the following table for what to do about serious side effects.

### SERIOUS SIDE EFFECTS OF ZOMIG NASAL SPRAY, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common (frequency greater than or equal to 1% but in less than 10% of patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irregular heart beat</td>
<td>🔄</td>
<td>🔄</td>
</tr>
<tr>
<td>Sensations of pain, pressure or tightness in the chest, neck, throat, jaw, arms, or legs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensations of tingling, heat, heaviness or pressure</td>
<td>🔄</td>
<td></td>
</tr>
<tr>
<td>Uncommon (frequency greater than or equal to 0.1% but in less than 1% of patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fast heart rate</td>
<td>🔄</td>
<td></td>
</tr>
<tr>
<td>Temporary increase in blood pressure</td>
<td>🔄</td>
<td></td>
</tr>
<tr>
<td>Rare (frequency greater than or equal to 0.01% but in less than 0.1% of patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shortness of breath, wheeziness, heart throbbing, allergic reactions including swelling of the eyelids, face, lips, mouth, tongue or neck; or a skin rash, itchy rash, skin lumps or hives, or swelling with fluid in the tissues</td>
<td></td>
<td>🔄</td>
</tr>
<tr>
<td>Very rare (frequency in less than 0.01% of patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptoms of a heart attack (chest pain, sweating, shortness of breath)</td>
<td></td>
<td>🔄</td>
</tr>
<tr>
<td>Sudden or severe abdominal pain or bloody diarrheaa</td>
<td>🔄</td>
<td></td>
</tr>
</tbody>
</table>

For any unexpected effects while taking ZOMIG Nasal Spray, contact your doctor or pharmacist.

HOW TO STORE IT

Keep your medicine in a safe place where children cannot reach it. ZOMIG Nasal Spray could be harmful to children. Store your medication between 15 and 30°C, away from direct heat.

If your doctor decides to stop your treatment, return your medicine to the pharmacist for disposal. Do not take your medication after the expiry date on the package. Return the unused nasal spray devices to your pharmacist for disposal.
**REPORTING SIDE EFFECTS**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

**MORE INFORMATION**

*NOTE: This INFORMATION FOR THE CONSUMER leaflet provides you with the most current information at the time of printing.*

For the most current information, the Consumer Information Leaflet plus the full Product Monograph, prepared for health professionals can be found at:

www.astrazeneca.ca or by contacting the sponsor, AstraZeneca Canada Inc. at:

Customer Inquiries – 1 (800) 668-6000,

This leaflet was prepared by AstraZeneca Canada Inc., Mississauga, Ontario, L4Y 1M4

ZOMIG® is a registered trademark of IPR Pharmaceuticals, Inc., used under license by AstraZeneca Canada Inc.

The AstraZeneca logo is a registered trademark of AstraZeneca AB, used under license by AstraZeneca Canada Inc.

©AstraZeneca 1998 - 2019

Last revised: December 11, 2019